Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Growth hormone therapy wikipedia , lookup
Metabolic syndrome wikipedia , lookup
Graves' disease wikipedia , lookup
Signs and symptoms of Graves' disease wikipedia , lookup
Diabetes mellitus type 2 wikipedia , lookup
Diabetes management wikipedia , lookup
Epigenetics of diabetes Type 2 wikipedia , lookup
1 0 8 Endocrine Disorders and the Heart Victor R. Lavis, Michalis K. Picolos, and James T. Willerson Hypothalamic-Pituitary Axis . . . . . . . . . . . . . . . . . . . . . Somatostatin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Prolactin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Adult Growth Hormone Deficiency. . . . . . . . . . . . . . . . Acromegaly . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Adrenal Insufficiency . . . . . . . . . . . . . . . . . . . . . . . . . . . Cushing’s Syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . Disorders of Mineralocorticoids . . . . . . . . . . . . . . . . . . . 2295 2296 2296 2296 2296 2298 2298 2300 Key Points • Increased mortality from cardiovascular disease among adults with hypopituitarism is perhaps related to growth hormone deficiency. • Major cardiovascular manifestations of acromegaly include cardiomegaly, cardiac hypertrophy, hypertension, congestive heart failure, coronary artery disease, and arrhythmias. • The excess mortality of acromegaly is abolished by successful treatment of acromegaly. • The major cardiovascular manifestation of adrenal insufficiency is arterial hypotension. • Major cardiovascular manifestations of Cushing’s syndrome include hypertension, myocardial hypertrophy, and a prothrombotic state. • The major cardiovascular manifestation of mineralocorticoid excess is hypertension, more common than previously thought. • Hypokalemia is important in mineralocorticoid disorders, but most patients are normokalemic. • Treatment with mineralocorticoid antagonist is beneficial following myocardial infarction and in congestive heart failure. • The major cardiovascular manifestation of pheochromocytoma is hypertension. • In pheochromocytoma, prompt treatment is important. • Metabolic syndrome is important as a risk factor for the development of atherosclerotic disease and type 2 diabetes mellitus. • The increased cardiovascular mortality in diabetes mellitus is reduced by aggressive treatment of multiple risk factors. Diseases of the Adrenal Medulla: Pheochromocytoma . . . . . . . . . . . . . . . . . . . . . . . . . . Diabetes Mellitus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Disorders of Calcium Metabolism . . . . . . . . . . . . . . . . . Hypothyroidism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hyperthyroidism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Carcinoid Syndrome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . Summary. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2301 2302 2307 2309 2312 2314 2315 • Intensive treatment of hyperglycemia reduces mortality in critical illness. • There is excess cardiovascular mortality in primary hyperparathyroidism. • The “euthyroid sick syndrome” results from nonthyroidal illness. • Major cardiovascular manifestations of hypothyroidism include bradycardia, cardiac enlargement, hypertension, low voltage on the ECG, and sometimes pericardial effusion. • “Subclinical hypothyroidism” is associated with increased lipids, but not yet conclusively linked to excess cardiovascular events. • Major cardiovascular manifestations of hyperthyroidism include tachycardia and tachyarrhythmias, atrial fibrillation, increased pulse pressure, and increased cardiac contractility with decreased reserve. • Overt and “subclinical” hyperthyroidism are linked to atrial fibrillation. • Major cardiovascular manifestations of carcinoid syndrome include tricuspid regurgitation and pulmonic valve damage related to right-sided endocardial plaques. • In carcinoid syndrome, there is increased morbidity and mortality in patients with carcinoid heart disease. Hypothalamic-Pituitary Axis This chapter reviews selected endocrine disorders and their influences on the cardiovascular system. The classic hormones of the anterior pituitary gland can be divided into three classes of related polypeptides: growth hormone (GH) and prolactin; adrenocorticotropin (ACTH) and other peptides derived from the pro-opiomelanocortin precursor; and 2295 CAR108.indd 2295 11/24/2006 10:58:03 AM 2296 chapter the glycoprotein hormones thyrotropin (thyroid-stimulating hormone, TSH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). Synthesis and secretion of pituitary hormones are regulated in part by hypothalamic neuropeptides. These neurohormones are transported from the hypothalamus via the pituitary portal circulation, thereby escaping dilution in the systemic circulation. They include growth hormone–releasing hormone (GHRH), somatostatin, thyrotropin-releasing hormone (TRH), dopamine, corticotropin-releasing hormone (CRH), and gonadotropin-releasing hormone (GnRH). Adrenocorticotropin and the glycoproteins have no major cardiovascular effects except those mediated by their respective target organs: the adrenal cortex, the thyroid, and the gonads. Somatostatin The term somatostatin encompasses a family of homologous peptides with multiple endocrine and paracrine actions. The major sources of somatostatins are the brain, the D cells of the pancreatic islets, and the gastrointestinal mucosa. Somatostatin from brain acts via the pituitary portal system to inhibit secretion of thyrotropin and growth hormone. In the endocrine pancreas, somatostatin inhibits secretion of insulin, glucagon, and somatostatin itself. Somatostatin also has diverse inhibitory effects on gastric and pancreatic exocrine secretion and on gastrointestinal activity. Somatostatin receptors, of which there are five subtypes, are widely distributed throughout the body.1 The various actions of somatostatin appear to be mediated by Gi proteins. Somatostatin may have a function in cardiac physiology, as it has been reported that cardiac nerves contain somatostatin.2 However, to date there has been no description of cardiac symptomatology in states of somatostatin excess. No clinical syndrome of somatostatin deficiency has yet been recognized. Uncontrolled studies have shown purported beneficial effects of treatment with octreotide, an analogue of somatostatin, in small numbers of patients with dilated or hypertrophic cardiomyopathy.3,4 These reports await confirmation in larger, randomized studies. Prolactin There is no established cardiovascular syndrome associated with excessive or deficient prolactin. One group of investigators has reported an association between hyperprolactinemia and venous thromboembolism,5 and has provided evidence that prolactin promotes adenosine diphosphate (ADP)-induced platelet activation.6 These results await confirmation. Adult Growth Hormone Deficiency Several studies have shown increased mortality from cardiovascular disease among adults with hypopituitarism.7 Some of this excess mortality may be related to deficiency of growth hormone.8,9 There is growing recognition of a syn- CAR108.indd 2296 10 8 drome of growth hormone deficiency in adults, the clinical features of which include loss of lean body mass, increased adiposity, muscular weakness, various psychological abnormalities, dyslipidemia, insulin resistance, abnormal endothelial function, osteopenia, bradycardia and impaired left ventricular systolic function.10–13 These features include several recognized cardiovascular risk factors. This problem should be suspected in individuals with known hypothalamic-pituitary disease of any etiology. For adults, the standard test for diagnosis of growth hormone deficiency has been the peak response of serum growth hormone to induced hypoglycemia.14 A synthetic analogue of hypothalamic growth hormone releasing hormone has become available and shows promise as a diagnostic agent that can avoid the risks of hypoglycemia.15 A deficiency of growth hormone can be treated with injections of recombinant human growth hormone. Treatment of adult GH deficiency increases left ventricular mass and indices of cardiac performance and exercise tolerance, and improves the lipid profile by increasing high-density lipoprotein (HDL) cholesterol and reducing low-density lipoprotein (LDL) cholesterol.16-18 However, to date there are no data regarding the effect of treatment on cardiovascular mortality. Acromegaly Pathophysiology Acromegaly is the clinical syndrome of excessive circulating GH with onset in adult life. It is nearly always caused by inappropriately high levels of GH secreted by a pituitary adenoma. Very rarely, it may be caused by secretion of GHRH by an extrapituitary tumor.19 Normally, secretion of GH from the anterior pituitary is regulated by the hypothalamic peptides, GHRH and somatostatin. There are several molecular variants of circulating GH, of which the relative physiologic significance remains to be elucidated.20 GH stimulates the production in various tissues of insulin-like growth factor-I (IGF-I, also known as somatomedin C) 21 and, to a lesser extent, IGF-II.22,23 These two peptides are structurally homologous to proinsulin.24 Many of the effects of growth hormone are mediated by the IGFs, especially by IGF-I.25,26 Growth hormone, acting directly or via IGFs, has a number of important metabolic effects. Broadly speaking, it promotes net protein anabolism while stimulating lipolysis and ketogenesis. As a result, lipid-derived fuels (i.e., nonesterified fatty acids and ketone bodies) are used for energy by various tissues, including myocardium. Amino acids are spared for protein synthesis. When GH is administered chronically, uptake and catabolism of glucose by muscle and adipose tissue are diminished, leading to insulin resistance and a tendency toward hyperglycemia.27 Echocardiographic studies indicate that administration of GH to humans increases heart rate and myocardial contractility.28 Clinical Manifestations The principal manifestations of acromegaly can be classified according to the organ systems affected. Growth of 11/24/2006 10:58:03 AM en docr in e disor ders a n d the he a rt bone in adults, in whom the epiphyses are closed, leads to broadening of the hands and feet, with increases in shoe, glove, and ring size. There is also enlargement of the mandible, with prognathism and dental malocclusion. Hypertrophic bone growth leads to osteoarthritis and nerve entrapment syndromes, which may be major causes of morbidity. Manifestations of soft tissue growth include thickened, greasy skin, enlargement of abdominal viscera, macroglossia, and goiter. Skin tags are common. An increased incidence of colonic polyps and colon cancer has been reported in patients with acromegaly.29–31 Metabolic manifestations include hypercalciuria and hyperphosphatemia. Hyperinsulinemia, indicative of insulin resistance, is found in most patients. However, clinical evidence of diabetes mellitus occurs in only approximately 10% of these individuals. The principal cardiovascular manifestations of acromegaly are cardiac hypertrophy, hypertension, premature coronary artery disease (CAD), congestive heart failure (CHF), and arrhythmias.11,32–37 Acromegaly is a serious disease. The major causes of death and disability are cardiovascular and respiratory disease, neoplasms, and degenerative joint disease.38 Age-specific mortality, principally from cardiovascular and respiratory complications, is increased from 1.5 to 3–fold.31 Arterial hypertension occurs in approximately 30% of people with acromegaly,39 especially those with longer duration of disease. The hypertension usually responds to medical treatment.40,41 In patients with acromegaly, there appears to be reduced activity of the renin-angiotensin-aldosterone axis,42,43 confirmed by pressor responses to angiotensin II antagonists,44 enhanced pressor responsiveness to angiotensin II,41 and increases in total exchangeable sodium.43 In addition, intravascular volume expansion occurs in many patients. Each of these alterations may contribute to the development of systemic arterial hypertension.41 Successful treatment of acromegaly reduces arterial pressure in many hypertensive acromegalic patients.33,41 Premature atherosclerosis occurs in some patients with acromegaly, but its prevalence is not clear. Virtually all patients with acromegaly have cardiomegaly, especially older individuals. The increase in cardiac mass, including asymmetric septal hypertrophy, is not directly related to hypertension. Some patients have left ventricular (LV) dilatation and reduction of ejection fraction. Clinical evidence of cardiomyopathy includes cardiomegaly, CHF, and occasional arrhythmias.11,34,45,46 Approximately 10% to 20% of patients with acromegaly have CHF, and in perhaps 20% of these there is no obvious predisposing cause. Diastolic dysfunction is found in some patients with acromegaly in the absence of hypertension or atherosclerosis.11,45,46 The CHF may be relatively resistant to conventional medical therapy. At autopsy, lymphocytic infiltration and small vessel disease of the myocardium34,37 have been found in some patients. Some histologic observations have demonstrated cellular hypertrophy, patchy fibrosis, and myofibrillar degeneration (Fig. 108.1). Autopsy studies of some patients after sudden death have demonstrated degenerative or inflammatory changes in the sinoatrial (SA) nerve plexus and the atrioventricular (AV) node.37 CAR108.indd 2297 2297 FIGURE 108.1. Histologic appearance of myocardium from a patient with acromegaly, showing hypertrophied fibers and interstitial fibrosis (IF). Mallory-Heidenhain stain, ×120. Diagnosis Because GH levels are highly variable, it is important to obtain them under standardized conditions. The most useful diagnostic test involves the oral administration of 75 to 100 g of glucose.19 In normal individuals, GH levels are less than 2 ng/mL, 90 to 120 minutes after administration of the test dose.47,48 Serum IGF-I levels, which correlate well with integrated measurements of GH,49 are also very helpful in diagnosis.50 In considering the possible diagnosis of acromegaly, it is also important to determine whether there are other alterations in pituitary or hypothalamic function. Treatment Recent surveys of large numbers of patients have shown that those with very low posttreatment GH levels exhibit no increase of mortality compared to the age-adjusted general population,31,51,52 highlighting the importance of reduction of excessive secretion of growth hormone. Criteria for successful treatment include normalization of both growth hormone and IGF-I levels.53 The recommended initial treatment in most cases is surgery, usually by the transsphenoidal approach.19,54,55 Reported surgical success rates depend on the size of the adenoma and on the stringency of the defi nition of cure (reviewed elsewhere54). Probably at least 40% of patients require some mode of adjunctive therapy, either drugs or irradiation.56 An effective treatment modality is administration of octreotide, an analogue of somatostatin.54,57 Treatment with octreotide decreases left ventricular mass in acromegalic patients with cardiac hypertrophy.58 Octreotide must be injected several times daily, but longer-acting analogues are available.59,60 Pegvisomant is a compound now available for clinical use that acts as an antagonist at the GH receptor. It has been shown to be effective in reducing IGF-I levels and ameliorating the clinical manifestations of acromegaly.61 Dopaminergic agonists, such as bromocriptine often provide subjective relief of symptoms, but do not significantly reduce GH levels in the majority of patients.19,54 11/24/2006 10:58:03 AM 2298 chapter Pituitary irradiation reduces GH levels slowly over several years, during which cardiovascular disease may progress.62 Also, irradiation carries a significant risk of late development of hypopituitarism, as well as brain damage or development of brain tumors.54,62,63 10 8 reduced LV dimensions and mitral valve prolapse, which disappeared with appropriate steroid replacement.66 Rarely, cardiomyopathy and heart failure have been reported as presenting manifestations of adrenal insufficiency.67,68 Diagnosis Adrenal Insufficiency Pathophysiology Adrenal insufficiency occurs when the secretion of adrenal glucocorticoids or mineralocorticoids is less than is needed by the body. Patients can develop adrenal insufficiency for one of several reasons. There may be failure of the pituitary to produce adequate amounts of ACTH, or diminished hypothalamic secretion of CRH, either as the result of hypothalamic disease or as a consequence of long-term treatment with pharmacologic doses of glucocorticoids. Primary failure of the adrenal cortex may be caused by (1) autoimmune disease associated with the development of antiadrenal antibodies, sometimes in association with pernicious anemia, autoimmune thyroid disease, diabetes mellitus type 1, or hypoparathyroidism; (2) destruction of the adrenal cortex by infection, especially tuberculosis, disseminated mycosis, or opportunistic infection, such as cytomegalovirus in patients with AIDS; (3) infarction or hemorrhagic necrosis associated with anticoagulation, the antiphospholipid syndrome or sepsis, especially meningococcemia; (4) rarely, cancer metastatic to the adrenals; or (5) a hereditary defect in organogenesis or the pathway of cortisol synthesis.64 Clinical Manifestations Primary adrenal insufficiency (Addison’s disease) can occur at any age and affects both sexes equally.65 Its major manifestations are weakness, increased skin or mucosal pigmentation, weight loss, anorexia, nausea, vomiting, and hypotension, often with postural hypotension. Hyponatremia, hypochloremia, and hyperkalemia are present in some of these individuals. Hyponatremia is caused by loss of sodium into the urine as the result of aldosterone deficiency, coupled with inability to excrete free water. Hyperkalemia occurs as a result of mineralocorticoid deficiency and reduction in the glomerular filtration rate. Hypercalcemia, probably related to volume contraction, may also be present. In patients with impaired secretion of ACTH, there is usually adequate secretion of mineralocorticoids by the adrenal zona glomerulosa, which continues to enjoy trophic stimulation by circulating angiotensins. Consequently, hyperkalemia is not usually a problem. However, because impaired excretion of free water is a consequence of glucocorticoid deficiency, hyponatremia may occur. Arterial hypotension is the most common cardiovascular finding in patients with adrenal insufficiency. Syncope occurs in many of these individuals. Heart size is normal or small, pulse volume is reduced, and orthostatic hypotension may be present. Echocardiographic studies of limited numbers of patients with Addison’s disease have shown CAR108.indd 2298 The most convenient screening test for adrenocortical insufficiency is measurement of plasma cortisol following intravenous injection of cosyntropin, a synthetic preparation of the 1 to 24 sequence of ACTH.69,70 For determination of the cause of adrenocortical insufficiency, there are several useful tests, including measurements of plasma ACTH levels and of plasma cortisol after prolonged infusion of cosyntropin.71 Treatment Treatment of adrenal insufficiency entails replacement of glucocorticoids as well as mineralocorticoids, if necessary. In previously untreated patients who manifest signs of volume depletion, the vascular compartment should be repleted with intravenous saline. Prompt administration of saline solution is especially important in Addisonian crisis, characterized by hypotension and cardiovascular collapse. As myocardial function may be reduced in this situation, one must monitor the patient carefully during volume resuscitation, in order to avoid pulmonary edema.72 In acute adrenal insufficiency or in patients experiencing physiologic stress, the dosage of glucocorticoid should be several times the usual daily maintenance dose. For treatment of acute adrenal crisis, the recommended dose of hydrocortisone is 100 mg IV q6h. Given in “stress” doses, hydrocortisone, the major natural glucocorticoid, exhibits substantial mineralocorticoid effects. As soon as the patient’s condition stabilizes, the dose of hydrocortisone should be reduced quickly to a maintenance dose. For maintenance therapy, either hydrocortisone or a less costly short-acting synthetic glucocorticoid, such as prednisone, should be given orally in physiologic replacement dosage (e.g., prednisone 5–7.5 mg daily, or hydrocortisone 15–20 mg in the morning and 5–10 mg in the afternoon). The usual injectable mineralocorticoid is desoxycorticosterone (DOC), and the oral preparation is fludrocortisone. The replacement dosage for mineralocorticoids should be determined on an individual basis. The usual replacement dosage of fludrocortisone is 0.05 to 0.2 mg daily, together with a liberal intake of dietary sodium. Hyperkalemia or elevation of plasma renin activity suggests the need for a higher dose of mineralocorticoid. Cushing’s Syndrome Pathophysiology Cushing’s syndrome results from the actions of excessive circulating glucocorticoids. Its most frequent cause is treatment with pharmacologic doses of antiinflammatory glucocorticoids for nonendocrine conditions. Most patients with endogenous Cushing’s syndrome have bilateral adrenal hyperplasia with resultant excess production of glucocorti- 11/24/2006 10:58:04 AM en docr in e disor ders a n d the he a rt coids, mineralocorticoids, and androgens. These patients usually have ACTH-producing tumors of the pituitary (Cushing’s disease) or ectopic ACTH production (e.g., from a lung cancer). Approximately 20% of cases of endogenous Cushing’s syndrome are ACTH-independent and are due to primary adrenal adenoma, carcinoma, or nodular dysplasia. Three times as many women as men have endogenous Cushing’s syndrome. Onset usually occurs in the third or fourth decade of life. Clinical Manifestations Depending on the cause of Cushing’s syndrome, the clinical picture may include the effects of increased androgens or mineralocorticoids in addition to those of glucocorticoids. Major manifestations are truncal obesity, plethora, systolic hypertension, proximal muscle weakness, thinning and fragility of the skin with ecchymoses and purple abdominal striae, hyperglycemia, osteoporosis, psychiatric disturbances, and fatigue.73 Many patients experience wide swings in mood, ranging from severe depression to frank psychosis or confusion. Overt diabetes mellitus is present in approximately 20% of patients. Hyperpigmentation, although uncommon, is a clue to hypersecretion of ACTH from the pituitary. In women with endogenous Cushing’s syndrome, hirsutism, a male escutcheon, amenorrhea, and deepening of the voice are due to androgen excess. The major signs of excessive mineralocorticoids are hypertension and hypokalemia (see below). Clinical Cardiovascular Manifestations Mortality is significantly increased in Cushing’s syndrome, related largely to cardiovascular problems.74 Even people with “subclinical” Cushing’s syndrome, characterized by autonomous cortisol secretion without absolute elevation of circulating cortisol levels, exhibit unfavorable cardiovascular risk profiles.75 The major cardiovascular abnormality is arterial hypertension, occurring in 80% of patients. Possible causes of the hypertension include volume expansion caused by mineralocorticoids and high levels of cortisol, increased production of angiotensin II, and vascular hyperreactivity.74,76 Unlike patients with essential hypertension, hypertensive patients with Cushing’s syndrome of any cause lack the normal nocturnal decline of blood pressure.77–79 As the normal diurnal rhythm of pituitary-adrenal secretion is disrupted in Cushing’s syndrome, blood pressure may normally be modulated by physiologic fluctuations of circulating adrenal steroids. Hemodynamic, electrocardiographic (ECG), and echocardiographic manifestations are usually associated with systemic arterial hypertension. There may be ECG or echocardiographic evidence of LV hypertrophy, left atrial (LA) enlargement, and, on occasion, evidence of diastolic dysfunction. Recent echocardiographic investigations suggest that increased LV wall thickness and asymmetric septal hypertrophy, with normal LV systolic function and diastolic dysfunction, are common findings in patients with endogenous Cushing’s syndrome of any cause.80–82 Chronic excess production of cortisol may also lead to hyperlipidemia, which can promote the development of CAR108.indd 2299 2299 atherosclerosis.83 Additionally, Cushing’s syndrome is a prothrombotic state, owing to increased circulating clotting factors and decreased fibrinolysis.84 Atrial myxomas and ACTH-independent Cushing’s syndrome may coexist in the Carney complex, a rare familial syndrome that comprises multiple small pigmented adrenal nodules; spotty cutaneous pigmentation including lentigines and blue nevi; subcutaneous, mammary, or cardiac myxomas; and other endocrine disorders such as acromegaly, thyroid adenomas, and testicular tumors.85 Diagnosis Dexamethasone, 1 mg given orally late in the evening, with measurement of plasma cortisol between 7 a.m. and 9 a.m. the next morning, serves as a sensitive screening test for endogenous Cushing’s syndrome.86,87 In normal individuals, serum cortisol levels will be less than 1.8 μg/dL with this test. Measurement of 24-hour urinary free cortisol serves as important confirmatory test.86,87 False-positive responses may occur with obesity, major depression, treatment with estrogen, or alcoholism, among other conditions. Discrimination of these conditions from true Cushing’s syndrome may be aided by measurement of plasma cortisol after suppression of ACTH secretion by dexamethasone, followed by stimulation with ovine CRH.88 For discrimination among the several causes of endogenous Cushing’s syndrome, various tests are available, including computed tomographic (CT) and magnetic resonance imaging (MRI) of the adrenal glands and pituitary, and measurement of cortisol levels after administration of ovine CRH, metyrapone, or graded doses of dexamethasone.89,90 In patients with ACTH-dependent endogenous Cushing’s syndrome, the aforementioned techniques may not distinguish unequivocally between pituitary and ectopic sources of ACTH. In this circumstance, determination of ACTH levels in the inferior petrosal sinuses after administration of ovine CRH has been reliable.90,91 A recent consensus conference has summarized guidelines for diagnosis and treatment of Cushing’s syndrome.86 Treatment Treatment of endogenous Cushing’s syndrome is dependent on the cause. For Cushing’s disease, transsphenoidal pituitary surgery, with or without irradiation, is most frequently employed. Surgical removal of the causative tumor should be attempted in patients with adrenal neoplasms and those with ectopic secretion of ACTH. Drugs that inhibit adrenal steroid synthesis are available for inoperable patients.92,93 Patients should be given anticoagulant prophylaxis for surgery and procedures.84 Hypertension associated with Cushing’s disease is usually treated with agents that block the effects of angiotensin II, often angiotensin-converting enzyme (ACE) inhibitors. Because hypokalemia is present in some patients with Cushing’s syndrome, diuretics must be prescribed with great care. Efforts should be made to replenish potassium, and if a diuretic is used, potassium-sparing diuretics or potassium supplementation in excess of what might be ordinarily required should be considered. In patients with hypokalemia, cardiac glycosides should be used with caution. 11/24/2006 10:58:04 AM 2300 chapter Disorders of Mineralocorticoids Pathophysiology Hyperaldosteronism was once thought to be rare. However, recent epidemiologic data suggest that autonomous secretion of aldosterone with suppression of the reninangiotensin system is present in up to 30% of individuals with hypertension.94,95 Hyperaldosteronism may arise from an adrenal adenoma or from bilateral adrenal hyperplasia.96,97 A similar syndrome caused by an excess of 11desoxycorticosterone or other mineralocorticoids can develop in patients with functioning adrenal tumors, Cushing’s disease, ectopic ACTH syndrome, and the 11β-hydroxylase or 17α-hydroxylase varieties of congenital adrenal hyperplasia.96,98,99 Other conditions that produce a similar clinical picture include (1) glucocorticoid-remediable hypertension, caused by inappropriate production of mineralocorticoids by the adrenal zona fasciculata100 ; (2) the syndrome of apparent mineralocorticoid excess, caused by action of cortisol on renal mineralocorticoid receptors owing to impaired renal inactivation of cortisol101; and (3) Liddle’s syndrome, owing to excessive renal reabsorption of sodium and excretion of potassium, caused by mutations in the epithelial sodium channel.102 In addition to the relationship of aldosterone secretion to hypertension, physiologic levels of mineralocorticoids may play an important role in heart disease. The high affinity (type 1) mineralocorticoid receptor, which has been identified in the heart, binds cortisol and mineralocorticoids with equal affinity. Hormonal specificity is provided by local type II 11ß-hydroxysteroid dehydrogenase (11ß-HSD), an enzyme that inactivates cortisol by converting it to cortisone.103,104 As cardiac activity of 11ß-HSD is low, both cortisol and aldosterone can bind to these receptors. In sodium-loaded rats, mineralocorticoids produce myocardial hypertrophy and fibrosis.105,106 Both experimental and clinical evidence suggest that aldosterone has roles in the pathophysiology of hypertension, inflammation, and endothelial dysfunction (reviewed elsewhere107). Clinical Manifestations The major clinical consequences of hyperaldosteronism are systemic arterial hypertension, hypokalemia, and metabolic alkalosis. Although not essential for the diagnosis of hyperaldosteronism, hypokalemia is important because it can predispose to development of frequent and complex ventricular arrhythmias. Polyuria and muscular weakness are other significant consequences of hypokalemia. Primary hyperaldosteronism may lead to LV hypertrophy and diastolic dysfunction, but malignant arterial hypertension is unusual. Diagnosis The most useful screening procedure for primary hyperaldosteronism is measurement of plasma renin and aldosterone in a patient with systemic arterial hypertension.108,109 An elevated ratio of aldosterone to renin (the exact number CAR108.indd 2300 10 8 depends on the assay for renin) suggests the diagnosis, which can be confirmed by lack of suppression of serum or urinary aldosterone during volume expansion or salt loading.110–112 Elevation of both renin activity and circulating aldosterone suggests secondary hyperaldosteronism associated with renal vascular disease, or with renal or cardiac failure.110–112 For the patient with primary hyperaldosteronism, it is important to discriminate adrenal adenoma from bilateral hyperplasia. Several tests have been developed for this purpose, including (1) CT of the adrenal glands; (2) measurement of the precursor steroid, 18–hydroxycorticosterone, which is usually markedly elevated in patients with adenoma; (3) response of plasma aldosterone to standing in the morning, with the level declining in patients with adenoma and rising in patients with hyperplasia; and (4) bilateral adrenal vein catheterization, with determination of ratios of aldosterone to cortisol.97,113 Treatment Surgical removal leads to cure of hypertension only in about 30% to 60% of patients with aldosterone-producing adrenal adenomas.114 Clinical attributes associated with successful surgery include age under 45 years, less than 5 years’ duration of hypertension, absence of a family history of hypertension, preoperative treatment with two or fewer antihypertensive drugs, and preoperative response to spironolactone.115,116 Medical therapy provides adequate control of hypokalemia and hypertension for patients with bilateral adrenal hyperplasia, and for many individuals with adrenal adenomas. Hyperaldosteronism can be treated with a competitive inhibitor of mineralocorticoid action, either spironolactone or eplerenone. Spironolactone has antiandrogenic activities that may produce gynecomastia and impotence, especially when doses greater than 200 mg/day are required.117 Eplerenone, which lacks these side effects, has recently been approved for clinical use (reviewed elsewhere118). In patients whose primary hyperaldosteronism is caused by bilateral hyperplasia, surgery is not usually effective. Therefore, treatment with spironolactone and other appropriate antihypertensive agents is preferred. Every effort should be made to replete serum potassium. Antagonism of mineralocorticoid action appears to have benefits in situations other than primary aldosteronism. In randomized clinical trials, treatment with mineralocorticoid receptor antagonists has reduced mortality in patients with severe CHF treated optimally with diuretics and ACE inhibitors,119 and among individuals with left ventricular dysfunction following myocardial infarction.120 The results of these clinical trials suggest that cardiac mineralocorticoid receptors are physiologically significant in humans. The role of mineralocorticoid receptor antagonism in treatment of heart disease has recently been reviewed.121–123 Hyperkalemia is a major side effect of treatment with mineralocorticoid antagonists, particularly when they are used in combination with ACE inhibitors or angiotensin receptor blockers, and in patients with diabetes and impaired renal function. When treating heart disease with mineralocorticoid antagonists, the clinician must remain alert to the risk of potentially dangerous hyperkalemia.124 11/24/2006 10:58:04 AM en docr in e disor ders a n d the he a rt Diseases of the Adrenal Medulla: Pheochromocytoma Pathophysiology Pheochromocytomas are tumors derived from chromaffin cells of the sympathetic nervous system, usually in the adrenal medulla (90% in adults and 70% in children). Their most important secretory products are the catecholamines norepinephrine and epinephrine. Biochemically and physiologically, the adrenal medulla is an integral part of the sympathetic nervous system. The location of adrenal medullary cells is associated with their ability to form epinephrine, as glucocorticoids secreted from the cortex pass in high concentration directly to the medulla, inducing the synthesis of phenylethanolamine-Nmethyltransferase, the enzyme that converts norepinephrine into epinephrine.125 Catecholamines stimulate glycogenolysis, gluconeogenesis, and lipolysis, inhibit secretion of insulin, increase systemic vascular resistance, and exert positive inotropic and chronotropic actions on the myocardium. The prevalence of pheochromocytoma was less than 0.05% in an autopsy series from Sydney,126 close to 0.5% in patients tested for hypertension, 1.9% in patients screened biochemically for suspicion of pheochromocytoma,127 and 4.2% among those with incidentally discovered adrenal nodules.128 In at least 10% of patients, the tumor is discovered incidentally during CT or MRI of the abdomen.129 The prevalence of malignancy in sporadic adrenal pheochromocytoma is 9%130 ; however, up to 36% of pheochromocytomas can be malignant depending on the genetic background and location of the tumor. Ten percent of patients have metastatic disease at the time of initial diagnosis.131 Ten percent of pheochromocytomas in adults and 35% in children are bilateral. Pheochromocytomas occur as part of a hereditary syndrome in up to 25% of patients.132 Approximately 5% of pheochromocytomas are inherited as part of one of the multiple endocrine neoplasia type II (MEN-II) syndromes, in which bilateral pheochromocytomas and medullary carcinoma of the thyroid coexist. The MEN-IIa syndrome may include hyperparathyroidism,133 and the MEN-IIb syndrome includes marfanoid habitus and multiple mucosal neuromas of the tongue, lips, gastrointestinal tract, or conjunctivae, usually without parathyroid disease.134 In the MEN-II syndromes, bilateral adrenal pheochromocytomas are the rule and mutations in the ret proto-oncogene on chromosome 10 can usually be identified. Pheochromocytomas may also coexist with the phakomatoses, including neurofibromatosis and von Hippel– Lindau disease, which includes, in addition, cerebellar or retinal hemangioblastomas, and renal and pancreatic tumors. Extraadrenal pheochromocytomas arising from the sympathetic ganglia are also called paragangliomas. About 85% of them are intraabdominal. Cardiac paragangliomas are extremely rare with about 50 cases reported in the literature. They have a characteristic appearance on transesophageal echocardiography.135 CAR108.indd 2301 2 3 01 Clinical Manifestations Pheochromocytoma is a rare cause of systemic arterial hypertension in humans, but the morbidity and mortality associated with these tumors is significant. These tumors produce paradoxical or sustained hypertension, often with postural hypotension, tachycardia inappropriate to the level of blood pressure, headaches, palpitations, chest pain, arrhythmias, profound sweating, signs of hypermetabolism, glucose intolerance, or hypertension after abdominal trauma or surgery. In a patient with hypertension, the coexistence of headache, sweating, and palpitations is highly suggestive of pheochromocytoma.136 In patients with pheochromocytoma, systemic arterial hypertension is typically paroxysmal but may be fi xed. Postural hypotension is common, caused by reduction of plasma volume or impairment of sympathetic reflexes.137,138 Electrocardiographic and echocardiographic manifestations in patients with pheochromocytoma are usually the result of systemic arterial hypertension. Electrocardiographic signs include evidence of LV hypertrophy, LA enlargement, left axis deviation, nonspecific ST-T wave changes, and ventricular and atrial arrhythmias. Occasionally, the ECG suggests the presence of myocardial ischemia during attacks of hypertension. The echocardiogram often demonstrates LV hypertrophy with relatively normal LV function. During a hypertensive crisis, the echocardiogram may demonstrate systolic anterior motion of the anterior leaflet of the mitral valve (“SAM pattern”) and paradoxical septal motion.139,140 The most common cardiovascular causes of death are arrhythmias and the consequences of systemic arterial hypertension, including strokes. Hypertrophic cardiomyopathy or a clinical picture indistinguishable from idiopathic dilated cardiomyopathy have been described. The chronic cardiomyopathy seems to depend on persistently high circulating levels of catecholamines because surgical removal of the tumor leads to significant improvement of cardiac function.141–144 Autopsy studies have demonstrated the presence of myocarditis in about half of patients who die from pheochromocytoma.143,145,146 Histologic findings include focal necrosis with infiltration of inflammatory cells, perivascular inflammation, and contraction band necrosis (Fig. 108.2). Scattered areas of fibrosis are also found. Diagnosis Hypertensive patients with any of the clinical problems noted above should be evaluated for pheochromocytoma, as detection may be lifesaving. Tests commonly employed for diagnosis include measurement of urinary catecholamines, vanillylmandelic acid (VMA), fractionated and total metanephrines, and measurement of serum catecholamines and plasma free metanephrines (metanephrine and normetanephrine). Vanillylmandelic acid and metanephrines are metabolites of catecholamines. Plasma-free metanephrines have sensitivity of 97% and 99% and specificity of 96% and 82% in detecting hereditary and sporadic disease, respectively. Urinary total metanephrines offer slightly higher specificity but are less sensitive, while fractionated urine metanephrines have sensitivity similar to the plasma-free 11/24/2006 10:58:04 AM 2302 chapter 10 8 disease.153,156 PET using 6–[18F]fluorodopamine is a recently introduced method that offers excellent visualization of primary and metastatic pheochromocytoma.157,158 Treatment FIGURE 108.2. Histologic appearance of myocardium from a patient with pheochromocytoma, showing myocarditis, nuclear degeneration of myocardial fibers, edema, and focal histiocytic infiltration. Hematoxylin and eosin (H&E) stain, ×285. metanephrines but lower specificity, especially for the detection of sporadic disease.147 In patients with paroxysmal hypertension, it is helpful to collect the urine and blood samples when blood pressure is elevated. In patients with equivocal results, clonidine suppression testing might be of further help.148 Imaging techniques for localization of pheochromocytoma include CT, MRI, nuclear scanning with 123I or 131Imetaiodobenzylguanidine (MIBG), somatostatin receptor imaging (SRI), and positron emission tomography (PET). Computed tomography has a sensitivity of 93% to 100% for detecting adrenal pheochromocytomas149 and about 90% for extraadrenal disease.150 Magnetic resonance imaging is superior for the detection of extraadrenal, juxtacardiac, and juxtavascular tumors.131,151 Both imaging methods have poor specificity, as low as 50%.152 Therefore, it is critically important to establish the diagnosis with biochemical tests, before proceeding to imaging studies. MIBG scanning is especially helpful for patients who have already had surgery and those who have malignant pheochromocytoma or tumors at unusual locations. Although not sensitive enough to exclude pheochromocytoma (77–90%), MIBG is highly specific (95– 100%).149,153–155 SRI has poor sensitivity (25% for adrenal pheochromocytoma) but may be particularly helpful for metastatic disease,154 paragangliomas, and MIBG scanning-negative CAR108.indd 2302 Pharmacologic therapy should be initiated as soon as the diagnosis of pheochromocytoma is made, to minimize the risk of life-threatening hypertensive crisis or arrhythmia. Adequate control of arterial blood pressure is mandatory before initiation of any diagnostic or therapeutic procedures, especially surgery to remove the pheochromocytoma. Traditionally, phenoxybenzamine hydrochloride has been used at an initial dose of 10 mg every 12 hours, which is gradually increased every 2 to 3 days until arterial blood pressure is normalized. Selective α1-receptor antagonists are acceptable alternatives, because they do not produce reflex tachycardia and have shorter duration of action and reduced duration of postoperative hypotension.130,159 During treatment with αadrenergic antagonists, sodium intake should be liberalized, as untreated patients are chronically volume depleted. One must be careful to detect postural hypotension associated with hypovolemia.136,160 β-receptor blocking agents may help in patients who have significant tachycardia, palpitations, and catecholamineinduced arrhythmias. However, it is important to establish α-adrenergic blockade before commencement of β-receptor blockade. If β-receptor blockade is begun before establishment of adequate α-receptor blockade, severe hypertension may occur as a result of unopposed α-adrenergic stimulation associated with the increase in circulating catecholamines. Calcium channel antagonists have been shown to control blood pressure and symptoms of pheochromocytoma. They can be used as alternatives to α-receptor antagonists or can be combined with selective α1-receptor antagonists. They reduce catecholamine production161 and inhibit norepinephrine mediated action on vascular smooth muscle.162 They may prevent catecholamine-induced coronary vasospasm and myocarditis, so they can be especially useful in managing patients with cardiovascular complications. They can be used safely in normotensive patients with episodes of paroxysmal hypertension.130 Surgical removal of the tumor can be accomplished after adequate blood pressure control is obtained. The anesthesiologist should be experienced in the management of these patients, with special regard to treatment of intraoperative tachyarrhythmias. Hypotension after tumor excision should be treated with aggressive volume repletion. Diabetes Mellitus Pathophysiology Diabetes mellitus is not a single disease but rather is a constellation of metabolic and pathologic abnormalities, with a variety of causes. Type 1 diabetes is caused by immunologically mediated destruction of the β cells of the pancreatic islets of Langerhans.163–165 Susceptibility to type 1 diabetes is determined by human leukocyte antigen (HLA) genotype,166 with the destructive process being triggered by some envi- 11/24/2006 10:58:04 AM en docr in e disor ders a n d the he a rt ronmental event, perhaps viral infection.164,167,168 Patients with type 1 diabetes mellitus may develop other endocrine manifestations of organ-specific autoimmunity, including chronic lymphocytic thyroiditis, Graves’ disease, and idiopathic adrenal insufficiency. Type 1 diabetes exhibits a predilection for Caucasians, and extreme geographic variability of prevalence. Since the peak incidence is during adolescence,169,170 type 1 diabetes has been called juvenile diabetes, although new cases occur throughout life, even into old age. Patients with type 1 diabetes usually eventually develop absolute deficiency of insulin, so they are prone to develop ketoacidosis unless treated regularly with exogenous insulin. In the United States, over 90% of patients with diabetes are characterized by strong hereditary predisposition unrelated to HLA type,167,171 and association with aging and obesity. This presentation of diabetes has been termed “type 2” but may be etiologically heterogeneous. Type 2 diabetes is the most common form of diabetes throughout the world. In the United States, it is the most prevalent form of diabetes among white people of European descent. Its prevalence is greater still among Native Americans, African Americans, and Mexican Americans. This form of diabetes is not accompanied by any detectable immunologic attack on the pancreas. Because the hyperglycemia is stable and does not lead to metabolic decompensation, type 2 diabetes may be present for a long time prior to diagnosis. Studies of the prevalence of retinopathy suggest that the mean duration of type 2 diabetes prior to diagnosis is at least 4 to 7 years.172 The pathophysiology of type 2 diabetes includes both insulin resistance, that is, impairment of the action of insulin, and abnormal secretion of insulin, especially in response to hyperglycemia.173–175 However, these patients usually have detectable and often substantial circulating insulin levels, especially early in the course of the disease. Although insulin secretory capability tends to decline over many years, most patients do not require exogenous insulin to prevent metabolic decompensation. Ketoacidosis ordinarily occurs only in the context of a stressful event, such as severe infection or infarction of an organ. The metabolic features of diabetes, which vary in severity from individual to individual, are those that are characteristic of inadequacy of insulin action. These abnormalities include (1) inadequately restrained catabolism of stored glycogen, triglycerides, and protein; (2) inappropriately increased gluconeogenesis; (3) decreased fractional utilization of circulating glucose by skeletal muscle and adipose tissue; and (4) accelerated ketogenesis in patients with absolute deficiency of insulin. These changes result in hyperglycemia, hyperlipidemia, and, in severe cases, net catabolism of protein. People with diabetes are especially prone to develop atherosclerotic disease, particularly coronary heart disease. The risk factors for initiation and progression of atherosclerosis are similar to those for development of type 2 diabetes, suggesting common pathogenetic mechanisms. The metabolic syndrome, known also as insulin resistance syndrome and syndrome X, consists of a set of physiologic attributes (Table 108.1) that share the property of being risk factors both for atherosclerotic events and for development of type 2 diabetes mellitus.176 These attributes tend to cluster in individuals, suggesting pathophysiologic linkage. For a given person, the CAR108.indd 2303 2303 TABLE 108.1. Components of the metabolic syndrome Abdominal obesity Dyslipidemia Small, dense LDL particles Low HDL-cholesterol Hypertriglyceridemia Hypertension Insulin resistance Hyperglycemia Proinflammatory state Prothrombotic state risk of a cardiovascular event is related to the number of components of the metabolic syndrome exhibited by that person.177,178 The metabolic syndrome may be viewed as the set of metabolically related risk factors that predispose to atherosclerotic disease. The primary abnormality has not been identified with certainty, although visceral obesity, insulin resistance, and inflammation are strong possibilities. Population surveys have shown this cluster of abnormalities to be present in about 85% of people with type 2 diabetes mellitus over the age of 50 years in the United States.179 In type 2 diabetes mellitus, much of the elevated cardiovascular risk seems to be attributable to the high prevalence of the metabolic syndrome.179 Obesity is a key component of the metabolic syndrome. Mounting evidence suggests that adipose tissue plays an important role in linking energy surplus and obesity to cardiovascular disease. Fat cells are not mere repositories for passive storage of excess fuel. They are metabolically highly active, and secrete a variety of mediators, known as adipokines, that influence the heart and circulation as well as insulin action (reviewed elsewhere180,181). The known adipokines include tumor necrosis factor-α (TNF-α), plasminogen activator inhibitor-1 (PAI-1), interleukin-6 (IL-6), and monocyte chemotactic protein-1 (MCP-1), which may contribute to systemic prothrombosis and generation of inflammatory mediators that may promote atherosclerosis (reviewed elsewhere182). Leptin is an adipokine, circulating levels of which are proportional to fat mass and energy surplus. Leptin has major roles in regulation of feeding and reproductive function.183,184 Its relation to cardiovascular disease has not been fully elucidated. Resistin is a secretory product of macrophages and adipose tissue that promotes insulin resistance185,186 and has been shown to influence endothelial cell function in vitro.187 Adiponectin, a 30–kd globular protein secreted by fat cells, is of special interest. Although produced by adipose tissue, circulating adiponectin levels are related inversely to obesity and insulin resistance.188,189 Moreover, clinical studies have shown low circulating adiponectin to be correlated with atherosclerotic events,190 suggesting that adiponectin protects against cardiovascular risk. Another recently described secretory product of fat cells is visfatin, which interacts with insulin receptors and mimics some of the actions of insulin; its physiologic role has not been elucidated.191 Premenopausal women with hyperandrogenism tend to be insulin resistant and to exhibit increased numbers of 11/24/2006 10:58:04 AM 2304 chapter cardiovascular risk factors, including elevated LDL cholesterol, hypertriglyceridemia, hypertension, increased waist circumference, and reduced adiponectin levels.192–194 Some studies have found increased arterial calcification and plaque in such individuals.195,196 Accordingly, hyperandrogenism seems to be linked to the metabolic syndrome. The relationship between excessive androgens and insulin resistance is complex. On the one hand, hyperandrogenism is part of the phenotype of impaired insulin receptor function, probably mediated by elevated circulating insulin, and treatments that improve insulin sensitivity tend to reduce androgen levels (reviewed elsewhere197,198). On the other hand, treatments that lower circulating androgens tend to improve insulin sensitivity to some extent.199,200 Clinical Manifestations The prevalence of diabetes mellitus is high, and rising. It is estimated that the lifetime risk of developing diabetes mellitus for an individual born in the United States in 2000 is on the order of 35% to 40%, and higher among women than men.201 The risk is especially high among Hispanic individuals, 45% and 52% for men and women, respectively.201 Moreover, diabetes mellitus is an important cause of death. Current United States mortality data suggest that the diagnosis of diabetes implies a 30% to 50% reduction of an individual’s remaining life expectancy.201 The major causes of death and disability in patients with diabetes include (1) atherosclerosis, manifested by occlusive coronary, cerebral, and peripheral vascular disease; (2) glomerulosclerosis leading to chronic renal failure; (3) arterial hypertension, which exacerbates cerebral vascular disease, renal insufficiency, and heart failure; (4) congestive heart failure, related to hypertension and ischemic heart disease; (5) peripheral and autonomic neuropathies; (6) proliferative retinopathy, the most common cause of blindness among working-age adults in the United States202 ; and (7) metabolic decompensation, including ketoacidosis and nonketotic hyperosmolar hyperglycemia. Microvascular disease produces widening of basement membranes of capillaries in the retina, conjunctiva, glomerulus, brain, pancreas, and myocardium.203–206 The clinical significance of these capillary lesions has not yet been fully elucidated. There is considerable evidence that control of hyperglycemia, hypertension, and dyslipidemia can help prevent the ocular, renal, neurologic, and vascular lesions that account for most of the death and disability in patients with both type 1 and type 2 diabetes.207–213 Type 2 diabetes tends to occur in individuals who are already burdened with various cardiovascular risk factors, including central adiposity; dyslipidemia consisting of elevated triglycerides, low HDL cholesterol, and small, dense LDL-cholesterol particles; hypertension; systemic inflammation; and a thrombotic tendency as indicated by elevated levels of circulating PAI-1.214–217 A number of potentially atherogenic abnormalities of plasma lipoproteins has been observed among people with diabetes. In poorly controlled type 1 diabetes, typically HDL cholesterol levels are reduced, with mild or no increase in very-low-density lipoprotein (VLDL) and LDL cholesterol. These alterations return to normal when metabolism is normalized with intensive insulin therapy.218 Rarely, patients CAR108.indd 2304 10 8 with long-standing insulin deficiency may display hyperchylomicronemia,219 owing to disappearance of lipoprotein lipase, which depends on insulin for its induction.220 The lipid pattern is different in type 2 diabetes mellitus, which is usually accompanied by obesity and insulin resistance. In this situation, one sees elevations of VLDL cholesterol and triglycerides, with reduced HDL cholesterol levels.218,221 Although LDL cholesterol levels may be normal, there is typically a shift in their size distribution toward smaller, denser particles, which are believed to be more atherogenic than the LDL of nondiabetic individuals.222–224 Control of hyperglycemia may improve LDL and triglyceride levels but is less effective in raising HDL.218 Epidemiologic studies show markedly increased cardiovascular mortality among persons with diabetes mellitus.225,226 Coronary artery disease, which leads to premature myocardial infarction (MI), is the leading cause of death among adults with diabetes. The presence of CAD correlates with the duration of diabetes. Additionally, in patients with type 2 diabetes, the level of glycemia is a risk factor for death from cardiovascular disease.227 Individuals with diabetes tend to have larger myocardial infarcts, a higher incidence of CHF, and higher mortality and morbidity rates associated with their infarcts than do nondiabetics.228–230 Survival after MI is reduced in diabetes, with mortality rates as high as 25% during the first year after infarction.228–230 Patients with diabetes mellitus have a higher incidence of painless infarcts than the normal population, with as many as 20% failing to experience pain during MI. Perhaps, because of autonomic neuropathy, many of these patients may experience recurrent myocardial ischemia without symptomatic angina.231,232 In people with diabetes, cardiac anginal threshold may be increased as a consequence of autonomic and sensory neuropathies. In one clinical series, the severity of cardiac dysfunction was related directly to the severity of cardiac autonomic neuropathy.233–235 Autonomic dysfunction sometimes results in fi xed heart rates that respond poorly to physiologic and pharmacologic interventions; this limits the ability of the heart to adjust cardiac output physiologically. Cardiovascular autonomic neuropathy is a strong risk factor for mortality in patients with diabetes.236,237 In animal models, experimentally induced diabetes results in ventricular dysfunction that may be at least partially corrected by the administration of insulin.238 Diabetic rats or rabbits develop a cardiomyopathy manifested functionally by decreased contractility, with slowing of both contraction and relaxation.238,239 These changes occur within a few months of induction of diabetes, and can be reversed by treatment of the diabetic animals with insulin for 4 weeks.238,239 In other experimental models, treatment with insulin does not correct abnormalities of ventricular function. Therefore, the explanation for development of cardiomyopathy in diabetes remains unclear. There is an increased risk for development of CHF in the diabetic patient, as established in the Framingham Study.240 This increased risk is present even when patients with prior coronary or rheumatic heart disease are excluded and the influences of age, blood pressure, weight, and cholesterol are taken into consideration.240 This argues for the existence of a diabetic cardiomyopathy. Noninvasive studies have revealed a variety of abnormalities in diabetic patients, including 11/24/2006 10:58:05 AM 2305 en docr in e disor ders a n d the he a rt increased fractional shortening during systole,241 asynchrony of early diastole,242 and slowed diastolic filling.243 These observations suggest that, at least in some individuals, there is a cardiomyopathy not based on the presence of myocardial ischemia.244 In patients with diabetes and cardiomyopathy, common histologic abnormalities are interstitial fibrosis (Fig. 108.3A), arteriolar hyalinization and narrowing of the lumina of intramyocardial arterioles245–249 (Fig. 108.3B). Diabetic dogs and humans exhibit diastolic dysfunction associated with interstitial deposition of periodic acid-Schiff (PAS)-positive glycoproteins243,250 (Fig. 108.3C). The combination of diabetes and hypertension seems to promote accelerated development of CAD and cardiomyopathy.251 Rats with experimental renovascular hypertension and diabetes develop myocardial fibrosis and hypertrophy,252 as well as microvascular abnormalities.253 These anatomic lesions are not seen in normotensive diabetic animals.253–255 Treatment with diltiazem reduces mortality in hypertensive diabetic rats, suggesting a pathogenic role for intracellular calcium.256 Other factors that may contribute to abnormalities in LV function in diabetics include hypertension, increases in GH that develop in patients with difficult-tocontrol diabetes, which may play a role in the increased col- lagen deposition in the LVs of some diabetics, and an alteration in calcium transport associated with increased sarcolemmal Ca–adenosine triphosphatase (ATPase) activity.257,258 Increases in sarcolemmal Ca-ATPase activity might result in a relative excess of calcium intracellularly, contributing to altered diastolic function and injury to heart muscle cells. Some experimental studies have suggested a beneficial effect of the slow channel calcium antagonist, verapamil in preventing diabetes-induced myocardial changes in experimental models.259 An interesting association with cardiomyopathy is a high prevalence of either septal hypertrophy or CHF in the infants of diabetic mothers.260 The cardiomyopathy in these infants may be transient and secondary to metabolic problems. In patients with diabetes, cardiovascular disease, hypertension, and nephropathy are closely interrelated. Nephropathy evolves over decades, beginning with glomerular hyperfiltration, followed by excretion of progressively greater amounts of plasma proteins, and culminating in renal failure.261 Thickening of mesangial matrix is characteristic of diabetic nephropathy, particularly in the glomerular tuft, where nodular glomerulosclerosis may be found.262 Microalbuminuria, defined as consistent excretion of more than A C B FIGURE 108.3. (A) Histologic appearance of myocardium from a patient with diabetes, showing arteriolosclerosis and interstitial fibrosis. (B) Histologic appearance of myocardium from a patient with diabetes, showing hyalinization of a small arteriole. H&E stain, ×300. Inset: Higher magnification of same arteriole (×50). (C) CAR108.indd 2305 Histologic appearance of myocardium from a patient with diabetes, showing circumferential periodic acid-Schiff (PAS)-positive material at the periphery of muscle fibers shown in cross-section PAS stain, ×210. 11/24/2006 10:58:05 AM 2306 chapter 20 μg of albumin per minute or more than 30 μg of albumin per milligram of creatinine in a random urine specimen,263 is an index of diabetic nephropathy that precedes declining excretory function. The presence of microalbuminuria predicts cardiovascular mortality264,265 as well as development of renal failure.266–269 Arterial hypertension270–272 and dyslipidemia273,274 are major risk factors for development and progression of diabetic nephropathy. Peripheral vascular disease is a significant problem for patients with diabetes mellitus (reviewed elsewhere275) and is a major factor leading to lower extremity amputation.276 Arteries in the legs below the knees are more likely to be involved by atherosclerosis in patients with diabetes than in those without diabetes.277 Noninvasive testing with ultrasound is more sensitive than medical history or physical examination for detection of peripheral arterial insufficiency.278 Cerebral vascular disease and infarction occur more frequently in people with diabetes. The renal vasculature may be affected by atherosclerosis in large vessels and by thickening of capillary basement membranes. Diagnosis Diabetes mellitus is diagnosed by measurement of circulating glucose levels. The glycemic criteria for diagnosis of diabetes have recently been revised 279 (Table 108.2). For example, reproducible fasting plasma glucose levels of greater than 126 mg/dL (7 mM) are considered diagnostic of diabetes. However, the cutoff values should not be interpreted too strictly, as there is no absolute defi nition of diabetes. Serum glucose values are continuously distributed in the population.280 Epidemiologic studies show an increased burden of cardiovascular risk factors281 as well as increased risk of cardiovascular events including death, among people with glucose levels in the upper part of the “normal” range.282–285 Postchallenge or postprandial glycemia seems to be more closely related to cardiovascular risk than is fasting glucose.286,287 Therefore, the finding of borderline hypergly- TABLE 108.2. Criteria for the diagnosis of diabetes mellitus Symptoms of diabetes and a casual plasma glucose >200 mg/dL. The classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss. Casual is defi ned as any time of day without regard to time since last meal. OR Fasting plasma glucose ≥126 mg/dL. Fasting is defi ned as no caloric intake for at least 8 hours. OR Two-hour plasma glucose ≥200 mg/dL during an oral glucose tolerance test. The glucose tolerance test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water. The patient should consume a high-carbohydrate diet for 3 days prior to performance of the test. In the absence of unequivocal hyperglycemia, these criteria should be confi rmed by repeat testing on a different day. CAR108.indd 2306 10 8 cemia or impaired glucose tolerance warrants close attention to all of the patient’s cardiovascular risk factors, even if treatment with a hypoglycemic drug is not deemed necessary. The diagnosis of diabetes is strengthened when there is corroborative evidence of diabetic retinopathy, peripheral and coronary vascular disease, peripheral neuropathy, or autonomic dysfunction. Prevention and Treatment The Diabetes Prevention Program showed that intensive lifestyle modification, including dietary intervention and an exercise program, delayed or prevented onset of type 2 diabetes in a diverse group of high-risk individuals with impaired glucose tolerance.288 In high-risk individuals with insulin resistance, progression from normoglycemia to overt diabetes mellitus appears to be related to declining insulin secretory responsiveness. In this situation, drugs that reduce demand for insulin might potentially block the development of hyperglycemia. In the Diabetes Prevention Program, treatment with metformin was effective, but less so than the lifestyle program. One study has shown that treatment with a thiazolidinedione seemed to slow the rate of decline of pancreatic insulin secretory capability in some women with a history of gestational diabetes.289 If this observation is confirmed in other populations, this class of drugs may be helpful for prevention of type 2 diabetes. Control of blood glucose levels is important for the prevention or retardation of the development of long-term morbidity and mortality in people with diabetes mellitus.212,213 Randomized clinical trials involving patients with both type 1 and type 2 diabetes have shown convincingly that intensive management of glycemia improves outcomes with regard to onset and progression of nephropathy, retinopathy, and neuropathy.208,209 It is less clear whether glycemia is closely related to progression of atherosclerosis.207,208,290 A randomized, prospective study of patients with type 2 diabetes has shown that intensive treatment of blood pressure reduced complications related to diabetes.291 A recent study has shown that intensive combined management of blood pressure, albuminuria, lipids, and glycemia reduced the risk of atherosclerotic and microvascular events by about 50%, among patients with type 2 diabetes mellitus and microalbuminuria.211 The relative importance of each of the individual interventions remains to be elucidated. Observational evidence suggests that hyperglycemia contributes to mortality among hospitalized patients.292 One randomized study showed that vigorous treatment of capillary glucose levels greater than 110 mg/dL, irrespective of any prior diagnosis of diabetes, reduced mortality in an intensive care unit from 8% to 4.6%.293 A recent meta-analysis implied that treatment with insulin reduces mortality among critically ill patients.294 A randomized, prospective study of patients admitted to the hospital with myocardial infarction, the Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study, showed improved in-hospital and postdischarge survival when hyperglycemia was treated aggressively with insulin and the patients were sent home on insulin, compared with “usual care.”295 In patients with type 1 diabetes mellitus, diet and insulin therapy are critical to management of hyperglycemia. For 11/24/2006 10:58:05 AM en docr in e disor ders a n d the he a rt patients with type 2 diabetes mellitus, diet and regular exercise can improve insulin resistance. Several oral agents, including sulfonylureas,296,297 meglitinides,298,299 metformin,300,301 α-glucosidase inhibitors, 302 and thiazolidinediones303,304 alone or in combination, may be effective in lowering glycemia.305 For reasons unknown, over time there is continuing decline of pancreatic secretory capability in type 2 diabetes,306 so treatment with insulin eventually becomes necessary for many patients. Insulin may be given alone, or combined with oral hypoglycemic agents.307–309 Treatment with thiazolidinediones increases circulating adiponectin and reduces levels of inflammatory markers, suggesting that these drugs might inhibit progression of atherosclerosis.310–312 A recent study showed a very modest reduction of cardiovascular events, coupled with increased risk of hospitalization for heart failure, in patients treated with pioglitazone.312a Treatment with thiazolidinediones tends to promote fluid retention, perhaps owing to vasodilatation or increased vascular permeability.313,314 About 5% of individuals treated with thiazolidinediones alone and about 15% of those treated with thiazolidinediones and insulin develop clinically significant edema.315–317 A recent retrospective survey found that 4.5% of patients on thiazolidinediones developed heart failure, versus 2.6% of those not on thiazolidinediones, over 8.5 months’ mean observation.318 The treatments were not assigned randomly, so it is not possible to estimate the risk of heart failure attributable to thiazolidinediones. However, clearly thiazolidinediones should be given very cautiously to patients at risk for development of heart failure. The American College of Cardiology and American Diabetes Association have recently published joint guidelines concerning this issue.319 Attempts at tight glycemic control entail a substantially increased risk of hypoglycemia, especially among individuals with type 1 diabetes, or advanced type 2 diabetes with minimal endogenous β-cell function. Patients being treated intensively with insulin may have few or no warning signs of hypoglycemia (hypoglycemic unawareness),320,321 as well as impaired spontaneous recovery from hypoglycemia (hypoglycemic unresponsiveness),320,322,323 adding to the risk for hypoglycemic brain damage. Much of this problem seems to be related to impairment of the autonomic response to hypoglycemia by prior episodes of hypoglycemia.324 Clinical studies have shown partial restoration of hypoglycemic awareness and responsiveness by scrupulous avoidance of hypoglycemia.325,326 Hypoglycemia during sleep has been linked to fatal cardiac arrhythmia—the “dead in bed” syndrome (reviewed elsewhere 327). The mechanism of arrhythmia has been postulated to be prolongation of the Q-T interval owing to sympathetic activation.328 The electrophysiologic changes can be prevented by infusion of potassium or βadrenergic blockade.328 It is important to choose antihypertensive drugs carefully. Guidelines for choosing antihypertensive drugs have been published.329 β-adrenergic blocking agents reduced complications in patients with type 2 diabetes330 but may entail special risks for patients with type 1 diabetes who are attempting strict blood sugar control. In such patients these drugs, especially the nonselective beta-blockers such as propranolol, may contribute to hypoglycemic unresponsiveness.331–334 In patients with preserved hypoglycemic CAR108.indd 2307 2307 responsiveness, beta-blockers will blunt the tachycardia but not the diaphoretic response to hypoglycemia.333,334 Furthermore, nonspecific beta-blockers may diminish pancreatic secretion of insulin,335,336 impair the responsiveness of tissues to insulin,335,336 elevate circulating triglycerides, and reduce plasma levels of HDL cholesterol.335,337,338 One must also be careful with diuretic therapy, which can cause deterioration of insulin resistance in patients with type 2 diabetes mellitus.339 Patients with diabetes should be screened for microalbuminuria, defined as consistent excretion of more than 20 μg of albumin per minute or 30 μg of albumin per milligram of creatinine in a random urine specimen.263 Currently, many clinicians consider inhibition or blockade of the renin-angiotensin-aldosterone system to be the strategy of first choice for treatment of albuminuria and hypertension in patients with diabetes. Angiotensin-converting enzyme inhibitors reduce albuminuria, prevent or retard the progression of diabetic nephropathy,340,341 and reduce mortality (reviewed elsewhere 342,343). Angiotensin II receptor antagonists also reduce albuminuria effectively, and provide further reduction of albuminuria when combined with ACE inhibitors (reviewed elsewhere 344,345). It is not yet known whether angiotensin II receptor antagonists confer a survival benefit.346 Patients started on ACE inhibitors or angiotensin II receptor antagonists should be checked for development of hyperkalemia and deterioration of glomerular filtration.347 Among patients with diabetes, hyperlipidemias appear to respond to the same dietary measures and drugs that are appropriate for nondiabetics.348,349 In patients with type 1 diabetes, excellent blood sugar regulation with insulin can produce normal circulating lipoprotein levels.350 Some recently published clinical trials confirm that reduction of LDL cholesterol levels by treatment with statins reduces the risk of cardiovascular events among people with diabetes.351–353 Based on this information, an expert panel has recommended an LDL cholesterol goal of <100 mg/dL for individuals with diabetes, with a more stringent goal of <70 mg/dL being a reasonable option for those at very high risk.354 It should be noted that nicotinic acid may exacerbate insulin resistance,355,356 requiring intensification of glycemic management. Disorders of Calcium Metabolism Pathophysiology Maintenance of the concentration of ionized calcium in extracellular fluid (ECF) within narrow limits is essential for normal neuromuscular excitability and for preservation of skeletal mass. The major hormonal regulator of ECF calcium is parathyroid hormone (PTH), a single-chain polypeptide of 84 amino acids. Its rate of secretion is inversely proportional to the concentration of ionized calcium over the physiologic range of calcium values in ECF.357,358 The relationship between extracellular ionized calcium and secretion of parathyroid hormone is governed by a calcium-sensing receptor protein, which is expressed on the surfaces of parathyroid and renal tubular cells.359–361 The primary physiologic effect of PTH is 11/24/2006 10:58:05 AM 2308 chapter to increase the concentration of ionized calcium in ECF. This is a result of augmentation of bone resorption, reduction of the fractional urinary excretion of filtered calcium, and stimulation of phosphaturia. In addition, PTH elevates serum calcium concentration by increasing the rate of conversion of 25–hydroxyvitamin D to 1,25–dihydroxyvitamin D, which enhances gastrointestinal absorption of calcium. Parathyroid hormone has a number of actions on the cardiovascular system, some but not all of which are mediated by hypercalcemia. Given in vivo or in vitro, PTH produces an increased heart rate, positive inotropic action, and cardiac hypertrophy.362,363 These changes are believed to result from entry of calcium into cardiac cells and from increased release of endogenous myocardial norepinephrine. Calcium and PTH-mediated activation of the protein kinase C cascade produces hypertrophic and metabolic effects on the cardiomyocyte.364,365 If PTH mediates excessive entry of calcium into cardiac muscle cells, it may also cause necrosis and depressed ventricular function. In addition, PTH has a direct vasodilatory effect on vascular smooth muscle, although it has not been established whether this is a physiologically relevant action of the hormone.365,366 The major causes of hypercalcemia include primary hyperparathyroidism, secretion of osteolytic factors (e.g., prostaglandins, cytokines, or PTH-related protein367,368) from a variety of neoplasms, excessive formation of 1,25–dihydroxyvitamin D by the granulomas of sarcoidosis or chronic infections such as tuberculosis, and the milk-alkali syndrome caused by ingestion of calcium and absorbable alkali.369 Primary hyperparathyroidism involves the excessive production of PTH. In many patients, primary hyperparathyroidism is asymptomatic and is discovered as an incidental result of routine laboratory testing. It is most often caused by a solitary parathyroid adenoma. Less frequently, there is generalized parathyroid hyperplasia or carcinoma of the parathyroid gland. The hypercalcemia associated with MEN-I and -II is usually caused by parathyroid hyperplasia. Germline mutations that decrease the sensitivity of the calcium-sensing receptor, also cause hypercalcemia.360,370 Heterozygotes for such mutations have an alteration in the set-point for regulation of PTH secretion,358 known as familial hypocalciuric hypercalcemia.360,370 Secondary hyperparathyroidism, most commonly associated with renal disease, gastrointestinal malabsorption, or a disorder of vitamin D economy, arises from chronic hypocalcemic stimulation of PTH secretion, resulting in hyperplasia of the parathyroid glands. Hypocalcemia most often arises from renal insufficiency with hyperphosphatemia, inadequate secretion of PTH (hypoparathyroidism), cellular resistance to the action of PTH (pseudohypoparathyroidism), or some disorder of vitamin D economy. The most important causes of hypoparathyroidism are surgical removal of the glands, usually as the unintended result of operations on the thyroid, and idiopathic hypoparathyroidism, often reflecting immunologically mediated destruction as part of one of the polyglandular autoimmune syndromes.371 Common problems with vitamin D include dietary deficiency, malabsorption, or some derangement in the multiorgan, multienzyme sequence that produces the fi nal active metabolite, 1,25–dihydroxyvitamin D. Hypovitaminosis D is a widespread health problem, particularly in the elderly and individuals with darker skin.372–374 CAR108.indd 2308 10 8 Clinical Manifestations The typical manifestations of hypercalcemia include polyuria, nocturia, nausea, vomiting, constipation, nonspecific joint and back pains, renal stones, nephrocalcinosis, and renal failure. There is also decreased neuromuscular excitability. In patients with very long-standing or severe hyperparathyroidism, elevation of serum alkaline phosphatase, osteopenia, localized brown tumors of bone, and spontaneous fractures may occur, caused by the effects of PTH on bone. In addition, elevation of urinary cyclic adenosine monophosphate reflects a direct effect of PTH on the kidneys. Some hypercalcemic patients develop systemic arterial hypertension.375 The precise mechanisms responsible for hypertension in such patients are unclear, as the levels of serum calcium are similar in those who are normotensive and those with hypertension. Increased serum calcium may render vascular smooth muscle more sensitive to agents, such as angiotensin II and norepinephrine. In patients with hypertension and hyperparathyroidism, the hypertension is not always reversible after surgical correction.376,377 Hypercalcemia impairs urinary concentrating ability (nephrogenic diabetes insipidus), leading to volume depletion. Deposition of calcium in the renal parenchyma may further impair renal function. Chronic hypercalcemia can lead to ventricular hypertrophy even in the absence of hypertension, and to deposition of calcium in the fibrous skeleton of the heart, the valvular tissue, coronary arteries, and myocardial fibers.378,379 The probability of extracellular deposition of calcium salts in the heart, lungs, kidneys, and other organs may be estimated by the product of circulating calcium and phosphorus. When the Ca × P (each in mg/dL) product is greater than 60, there is a risk of metastatic calcification; Ca × P products over 75 indicate a severe risk. Increases in extracellular calcium lead to subsequent increases in intracellular calcium and may provoke arrhythmias, including fibrillation in isolated cardiac muscle cells.380 Marked hypercalcemia shortens the Q-T interval and may lead to ventricular arrhythmias and sudden death in humans. Patients with primary hyperparathyroidism are reported to have overrepresentation of cardiovascular death in population studies.381–384 Postulated mediators of this phenomenon385,386 include hypertension,387 disturbances in the renin-angiotensin system,388 cardiac arrhythmias,389,390 structural and functional abnormalities of the vascular wall391–395 and cardiac muscle,396–400 insulin resistance,401 and hyperlipidemia.402 Whether asymptomatic primary hyperparathyroidism confers increased mortality remains to be determined.386 Hypocalcemia typically produces tetany and other manifestations of neuromuscular hyperexcitability.403 The ECG effects of hypocalcemia include prolongation of the Q-T interval and arrhythmias, especially torsades de pointes.404 In addition, decreases in gastrointestinal motility are often present. Hypoparathyroidism may cause a dilated cardiomyopathy, presumably secondary to hypocalcemia.405–410 In these situations, hypomagnesemia and reduced circulating PTH may also contribute.406,411 Hypovitaminosis D causes rickets in children and osteomalacia in adults.412 It has also 11/24/2006 10:58:05 AM en docr in e disor ders a n d the he a rt been linked with increased risk of hypertension,413,414 congestive heart failure,415,416 multiple sclerosis,417 cancer,418–420 and type 1 diabetes mellitus.421 Diagnosis Evaluation of a hypercalcemic patient should begin with measurement of the ionized fraction of circulating calcium. If ionized hypercalcemia is confirmed, the next step in differential diagnosis should be determination of PTH dependence by measurement of intact PTH with a second-generation immunoradiometric assay that is highly specific for the full length 84-amino-acid peptide.422,423 The combination of hypercalcemia and unequivocally elevated PTH levels most often indicates parathyroid adenoma or hyperplasia. However, one should exclude the diagnosis of familial hypocalciuric hypercalcemia (vide supra) 360. This autosomal dominant condition is characterized by moderate hypercalcemia with some elevation of PTH levels. Heterozygotes exhibit a benign course, usually without renal or osseous complications,424,425 and require no specific treatment. Although the parathyroid glands are usually hyperplastic, parathyroidectomy is of no benefit in familial hypocalciuric hypercalcemia.424,425 The keys to diagnosis are ascertainment of other affected family members and measurement of urinary calcium excretion. In patients with familial hypocalciuric hypercalcemia, the ratio of calcium to creatinine clearances is less than 0.01.424,425 In a hypocalcemic patient, hypoparathyroidism can be confirmed by demonstration of inappropriately low serum PTH concentration together with an increased serum phosphorus level. If the PTH level measured by a full-length second-generation immunoradiometric assay is not low, one should search for another cause of hypocalcemia. In hypovitaminosis D, serum 25-hydroxyvitamin D concentration is low,412,426 but circulating 1,25-dihydroxyvitamin D may be normal. Serum calcium usually remains in the normal range due to compensatory elevation of PTH.427,428 Treatment Owing to the use of multichannel screening tests, hyperparathyroidism is frequently discovered in individuals who are relatively asymptomatic. Many of these asymptomatic patients pursue a relatively benign course, without development of renal insufficiency, urinary stones, or significant bone disease. At present there is no reliable criterion for prospective identification of this subset of patients.429 The consensus of experts is that if the patient’s operative risk is reasonable, parathyroidectomy is recommended for patients with any of the following conditions430 : • Serum calcium concentration greater than 1 mg/dL above the upper limits of normal • Twenty-four-hour urinary calcium greater than 400 mg • Creatinine clearance reduced by more than 30% compared with age-matched subjects • Low bone density of lumbar spine, hip, or radius • Age younger than 50 years • Medical surveillance is not desired or possible Hyperparathyroid patients who do not undergo surgery should be followed closely, with periodic measurements of CAR108.indd 2309 2309 serum calcium and PTH, creatinine clearance, calcium excretion, and bone mineral density. Calcimimetics are a new class of medications that interact with the calcium-sensing receptor on the parathyroid cell. They increase the sensitivity of the receptor to extracellular calcium ions and inhibit the release of parathyroid hormone.431,432 Cinacalcet, a second-generation ligand of this class, has been approved for the treatment of hypercalcemia in patients with parathyroid cancer or for dialysis patients with secondary hyperparathyroidism.433–435 A recent doubleblind randomized clinical study showed that treatment with cinacalcet maintained normocalcemia over 40 weeks in a group of patients with primary hyperparathyroidism.436 Drugs of this type may become a useful alternative to parathyroidectomy in patients with primary hyperparathyroidism.434 The first step in medical treatment of moderate or severe symptomatic hypercalcemia of any cause should be restoration of extracellular volume with isotonic fluids.437,438 After volume expansion, cautious intravenous administration of a loop diuretic such as furosemide will promote excretion of calcium. If these measures do not lower the serum calcium satisfactorily, several effective drugs are available. These include subcutaneous calcitonin and bisphosphonates such as intravenous pamidronate.438–441 Glucocorticoids are employed for treatment of hypercalcemia caused by excessive circulating 1,25–dihydroxyvitamin D or by some hematologic malignancies.438,442 Hemodialysis remains an option in cases of life-threatening hypercalcemia unresponsive to initial medical management. Treatment of hypertension or edema in patients with hypercalcemia should not include thiazide diuretics, which promote renal reabsorption of calcium and thereby elevate the serum calcium concentration.443,444 In patients with hypoparathyroidism, supplementation of calcium is provided by the administration of calcium, and vitamin D or one of its metabolites to enhance the intestinal absorption of calcium. Hypovitaminosis D can be treated with oral vitamin D (ergocalciferol), 50,000 IU weekly for 8 weeks and maintenance doses after that.445 Hypothyroidism Pathophysiology Approximately 90% of normal thyroidal hormone secretion is in the form of thyroxine (T4), which is thought to be a prohormone. About 99.98% of circulating T4 is bound with high affinity but reversibly to plasma proteins, primarily thyroxine-binding globulin (TBG) and secondarily transthyretin (thyroxine-binding prealbumin). Thyroid hormone action is exerted principally by triiodothyronine (T3), which is formed by 5′-deiodination of T4 in the liver and other target tissues. The major actions of T3 are believed to be mediated by interaction with specific receptors in cell nuclei. T3 receptors, of which several variants have been described, are members of the steroid receptor superfamily.446,447 Initiation of hormonal effects involves a three-way interaction among T3, T3 receptors, and specific base sequences of DNA. As a consequence of this binding, alterations occur in gene 11/24/2006 10:58:06 AM 2 310 chapter transcription and protein synthesis, leading to many of the biochemical and metabolic effects observed with administration of thyroid hormone. The actions of thyroid hormones on the cardiovascular system have been extensively studied.448 Thyroid hormones increase cardiac contractility and heart rate. Increased wholebody oxygen consumption, decreased systemic vascular resistance, expansion of blood volume, and direct effects of thyroid hormone on the myocardium all may play roles in mediation of these responses.449–451 Some investigators have reported that thyroid hormone increases cardiac sensitivity to catecholamines, but this effect remains controversial.449 At the cellular level, thyroid hormone increases the activity of plasma membrane Na,K-ATPase, perhaps by stimulation of synthesis of enzyme subunits. This action results in augmented hydrolysis of adenosine triphosphate (ATP) at the site of the sarcolemmal sodium pump, which stimulates cellular oxygen consumption. Thyroid hormone also affects other cellular processes, including transport of glucose and calcium and synthesis of myosin. The net effect of thyroid hormone on sarcolemmal calcium transport is to enhance myocardial relaxation.452,453 In rats and rabbits, treatment with thyroid hormone increases the amount of the mobile cardiac myosin isoenzyme (V1), whereas the slower V3 myosin isoform is reduced.454 This effect is less prominent in human myocardium. The augmented myosin ATPase activity of the hyperthyroid heart appears to contribute to the enhanced contractile response, since the activity of this enzyme regulates the rate of turnover of actin-myosin cross-bridge linkages in cardiac muscle. The influence of thyroid hormone on myosin isoenzymes appears to be localized primarily in the ventricles. Hypothyroidism induces the opposite effects.454,455 Thyroid hormone also increases peak tension development while shortening the duration of contraction in ventricular muscle. These effects may be related to a more rapid intracellular calcium transient, owing to an increase in the number of slow calcium channels with accelerated reuptake of calcium by the sarcoplasmic reticulum.456–458 Some have suggested that the effects of thyroid hormone on protein synthesis and on myosin isoenzymes in the heart are results of changes in cardiac work rather than direct hormone actions.459,460 Hypothyroidism is caused by reduced secretion of thyroid hormones, usually as a consequence of destruction of the thyroid gland, often mediated by an autoimmune process, and sometimes following thyroidal surgery or treatment with 131I. Occasionally, hypothyroidism results from decreased secretion of TSH, owing to pituitary or hypothalamic disease. With secondary hypothyroidism, the signs and symptoms associated with deficiency of other pituitary hormones are often present. Subclinical hypothyroidism resulting from mild thyroid failure is defi ned as an elevated serum TSH concentration with free T4 in the reference range.461 The antiarrhythmic drug amiodarone has complex effects on pituitary-thyroid physiology.462 Patients who receive it are subjected to an immense pharmacologic overload of iodine, which makes up 37% of the weight of the drug. Amiodarone is stored in adipose tissue, from which iodide is slowly released into the circulation by slow deiodination.463,464 Amiodarone, in common with other organic iodides, inhibits the CAR108.indd 2310 10 8 peripheral and pituitary forms of 5′-deiodinase, the enzymes that convert T4 to T3.464,465 This releases TSH secretion from feedback inhibition by circulating T4, and slows the clearance of T4 from the circulation. The normal physiologic response to amiodarone includes elevation of circulating T4 levels, as well as increases of plasma TSH, which usually return to normal after about 3 months of treatment. Additionally, amiodarone may produce hypothyroidism or thyrotoxicosis. In countries with abundant environmental iodine, such as the United States, amiodarone-induced hypothyroidism is more common than thyrotoxicosis.463 Amiodarone may cause an increase in intrathyroidal Ia-positive T cells, an abnormality found in patients with spontaneous Graves’ disease. T-cell abnormalities disappear after discontinuation of amiodarone. Amiodarone may also produce a syndrome of painful inflammatory thyroiditis.466 Clinical Manifestations Hypothyroidism is twice as common among women as men. The peak of incidence is between the ages of 30 and 60 years. Characteristic symptoms include cold intolerance, dryness of the skin, weakness, impairment of memory and intellectual function, personality change, constipation, hoarseness, and menstrual abnormalities. A case-control study showed that individual symptoms such as fatigability are poor discriminators, but combinations of symptoms may identify hypothyroid individuals.467 Typical physical findings include cool, dry skin, slowed mentation and speech, facial puffiness, and nonpitting edema (myxedema) of the lower extremities. Myxedema reflects a generalized tendency to accumulation of mucopolysaccharide-rich interstitial fluid, which may also be manifested as puffiness of the face and eyes, ascites, pleural or joint effusions, and pericardial effusion (see later). Other classic findings include delayed relaxation of skeletal muscle, as manifested in the Achilles tendon reflex, and development of a yellowish hue to the skin, resulting from decreased conversion of carotene to vitamin A. Classical cardiovascular physical findings include bradycardia, cardiac enlargement, distant heart sounds, weak arterial pulses, and nonpitting peripheral edema. Electrocardiographic findings include sinus bradycardia, atrioventricular and intraventricular conduction defects, and low voltage. Although hypothyroidism prolongs the cardiac action potential and QT interval, potentially predisposing to cardiac irritability, ventricular arrhythmias and in rare cases torsades de pointes468,469 arrhythmias are infrequent in hypothyroid patients.470 Hemodynamically, the hypothyroid state is characterized by bradycardia, decreased myocardial contractility, and increased total peripheral resistance.471 Blood and plasma volumes are reduced, as are stroke volume and cardiac output. Overt hypothyroidism is associated with higher blood pressure in patients with systemic hypertension.472–474 Ten percent to 25% of hypothyroid patients have diastolic hypertension, which combined with the increase in vascular resistance increases cardiac afterload.449,475 Although cardiac enlargement is typical, overt CHF is uncommon.476–479 When it occurs, CHF is caused by dilated cardiomyopathy.471 Another important cause of cardiomegaly in hypothyroidism is pericardial effusion, which occurs in up to 30% of hypothyroid 11/24/2006 10:58:06 AM en docr in e disor ders a n d the he a rt patients.471 The effusion is one manifestation of a generalized leakage of protein-rich fluid into interstitial spaces. Cardiac tamponade is unusual but has on occasion been reported as the presenting sign of hypothyroidism.480 Extensive CAD may be present in hypothyroid patients. Coronary atherosclerosis occurs with twice the frequency in patients with myxedema compared with age-and sex-matched control subjects.481 Subclinical hypothyroidism has been reported to be associated with LV diastolic dysfunction at rest and with exercise,482–486 impaired flow-mediated vasodilatation indicating endothelial dysfunction, and decreased heart rate variability indicating autonomic dysfunction.487 Enhanced risk for atherosclerosis and increased cardiovascular risk has been reported,482,488 perhaps related to atherogenic lipid abnormalities: mildly increased levels of total cholesterol, LDL cholesterol, and oxidized LDL.448,489–491 However, a recent systematic review did not find adequate evidence linking subclinical hypothyroidism to either cardiac dysfunction or unfavorable cardiovascular outcomes.492 Diagnosis The typical symptoms and physical examination of a patient with hypothyroidism aid in recognition of the condition. However, as is true for hyperthyroidism, in elderly patients some of the classic clinical manifestations of hypothyroidism may be subtle or nonexistent.471 Hyponatremia, hyperprolactinemia, hyperhomocysteinemia, hypoglycemia, hypercholesterolemia, and hypertriglyceridemia may be caused by hypothyroidism.493–495 Hypothyroid patients may also have elevated skeletal muscle enzymes, including creatine kinase (CK-MM band), lactic dehydrogenase (LDH), and serum glutamic-oxaloacetic transaminase [SGOT, aspartate aminotransferase (AST)]. The mechanism by which these skeletal muscle enzymes are increased chronically in patients with hypothyroidism is unclear. Measurements of TSH and of serum free T4 index are the most helpful clinically, with the combination of low serum free T4 index and increased TSH concentration being diagnostic of primary hypothyroidism. Treatment Patients with hypothyroidism should be treated with T4.496 Precipitation or worsening of myocardial ischemia during treatment of hypothyroidism is a clinically important problem.497 Accordingly, most authors recommend a low starting dose of T4, on the order of 0.025 or even 0.012 mg daily, in elderly patients and those predisposed to ischemic heart disease.496 With such patients, it may be prudent to titrate the dose to less than full replacement levels. For patients at less risk for myocardial ischemia, the starting dose of T4 may be 0.05 mg/day.498,499 The dose may be increased every 4 to 6 weeks until the TSH level is normalized. The usual maintenance dose for adults is about 0.1 to 0.125 mg/ day.498,499 During this treatment, the patient’s cardiovascular condition should be monitored carefully. If there is worsening of angina or a marked increase in heart rate or blood pressure, the dose should be reduced to eliminate these effects. In patients with intact pituitary glands, measure- CAR108.indd 2311 2 311 ment of serum TSH levels provides the most useful marker of the adequacy of replacement therapy. Whether persons with subclinical hypothyroidism and serum TSH less than 10 mIU/L should be treated remains controversial.492,500 No blinded randomized controlled study has assessed the impact of thyroxine treatment on important clinical cardiac end points.492,501,502 Treating heart failure in the patient with myxedema is somewhat more complicated than in euthyroid individuals, because people with myxedema are often unusually sensitive to the effects of cardiac glycosides. Patients with unstable or limiting angina and untreated myxedema pose a particularly difficult clinical problem because angina may be exacerbated or an MI may be caused by too vigorous thyroid hormone replacement. One should replace thyroid hormone very carefully in such individuals, administering small doses as indicated above and initially attempting to make the patient comfortable rather than euthyroid. In the patient with extensive CAD and unstable angina, surgical revascularization can be accomplished in association with low-dose thyroid hormone replacement, followed later by full thyroid replacement during the postoperative period. Perioperative morbidity is only slightly increased for patients with mild to moderate hypothyroidism.503,504 Therefore, necessary cardiovascular surgery need not be postponed until the euthyroid state is restored. In the patient with CHF and myxedema without CAD, administration of thyroid hormone carefully and in increasing amounts, in association with the use of a diuretic, salt restriction, and digoxin in appropriately small doses, usually leads to the control of CHF in time. Acutely or chronically ill patients often have low serum T4 and T3 values without elevation of circulating TSH, a situation known as the “euthyroid sick” syndrome.505–510 The thyroid hormone levels are inversely correlated with survival.511 The low T3 values are secondary to decreased extrathyroidal 5′-deiodinase activity, with reduced conversion of T4 to T3.508,509 The reduced T4 levels are often related to alterations in protein binding of circulating T4, causing a decrease in total T4 but only minimal changes in the level of physiologically active free hormone.508,509,512 There may also be suppression of TSH release, owing to severe medical illness or drugs such as dopamine. In the euthyroid sick syndrome, the serum TSH is not elevated, but may increase in the recovery period.508–510 In difficult cases, further diagnostic discrimination may be obtained by measurement of serum 3,3′,5′triiodothyronine (reverse T3), the concentration of which typically rises in the euthyroid sick syndrome but declines in hypothyroidism.508,509 There is controversy regarding whether individuals with the euthyroid sick syndrome are physiologically hypothyroid, but administration of T4 or T3 does not improve prognosis.507,513 Many patients with acute or chronic cardiac disease exhibit the euthyroid sick syndrome. Within 4 hours after acute MI, T3 and T4 levels are reduced by about 20% and 40%, respectively.514 In patients with chronic heart failure, circulating thyroid hormone concentration decreases and reverse T3 increases parallel to the degree of functional impairment.515 Circulating T3 levels fall significantly in the postoperative period of patients undergoing cardiopulmonary surgery or coronary artery bypass.516–518 This alteration in thyroid status might modify cardiac gene expression and 11/24/2006 10:58:06 AM 2 312 chapter contribute to impaired cardiac function.448,519 Although some data imply that the administration of T3 may benefit some patients with cardiovascular disease, beneficial effects on major clinical outcome variables have not been conclusively demonstrated.448,449,517,520 Hyperthyroidism Pathophysiology Thyrotoxicosis, which is defined as the state of excessive circulating thyroid hormone, can have a variety of causes. The most frequent are (1) production of circulating autoantibodies that activate TSH receptors, producing diffuse toxic goiter (Graves’ disease); (2) toxic multinodular goiter or hyperfunctioning solitary thyroid adenoma; (3) subacute thyroiditis; and (4) postpartum and “silent” thyroiditis, probably of autoimmune cause.521 Less common causes include TSHsecreting adenoma of the pituitary, massive overproduction of chorionic gonadotropin or another low-potency thyroid stimulator in patients with hyperemesis gravidarum or trophoblastic neoplasm,522,523 and accidental or purposeful ingestion of thyroid hormone (thyrotoxicosis factitia). Subclinical hyperthyroidism is characterized by subnormal or suppressed serum TSH concentration with circulating thyroid hormones in the reference range.500 It may be due to dysfunction of the thyroid gland (endogenous subclinical hyperthyroidism) but more often is the consequence of treatment with l-thyroxine (exogenous subclinical hyperthyroidism).482,492 Clinical Manifestations Patients with thyrotoxicosis typically have heat intolerance; warm, moist skin; brittle nails and hair; tremulousness; irritability and emotional lability; increased appetite; weight loss; resting heart rates greater than 90 beats/min; palpitations; muscle weakness; and menstrual abnormalities. On physical examination, a thyrotoxic patient typically has a very active precordium with a right ventricular (RV) lift, a palpable pulmonary artery, an enlarged heart, and a systolic ejection murmur. The patient may also have brisk reflexes, a prominent stare, lid lag, a wide pulse pressure, and bounding peripheral pulses. Proptosis and paralyses of extraocular muscles, when they occur, point to Graves’ disease as the cause of thyrotoxicosis. In the young individual, thyrotoxicosis is usually relatively easy to identify, but in elderly patients the typical clinical features may be lacking or far more subtle. Palpable thyroid enlargement or a nodule is present in most patients, but these signs may be absent. Therefore, the diagnosis of thyrotoxicosis may be delayed or overlooked for long periods of time. Excessive thyroid hormone causes increases in heart rate, cardiac contractility, and pulse pressure.524–526 Left ventricular ejection fraction and cardiac output are increased at rest but do not appropriately adapt to exercise due to ineffective and impaired chronotropic, contractile, and vasodilatory cardiovascular reserves. This effect, reversible with restoration of the euthyroid state, can explain the reduced exercise toler- CAR108.indd 2312 10 8 ance of hyperthyroid patients.451,527,528 Prolonged exposure to even slightly increased amounts of thyroid hormone can lead to cardiac hypertrophy.529 High-output heart failure coexists with thyrotoxicosis in some patients. Cardiac dilatation and hypertrophy, markedly increased cardiac output, and ultimately heart failure may develop. The tachycardia of hyperthyroidism appears to arise from the actions of thyroid hormones on several different ion channels in the cells of the SA node.530 Heart rate variability is attenuated, suggesting impaired autonomic regulation.531 Although many of the cardiovascular manifestations of hyperthyroidism resemble a heightened β-adrenergic state, careful physiologic studies have not shown altered sensitivity of the cardiovascular system to adrenergic stimulation.448,449,451,532–534 Atrial fibrillation with rapid ventricular rate is a particular problem.525,526 It occurs in 5% to 15% of patients with hyperthyroidism and may be the initial reason for medical evaluation.535–537 Although hyperthyroidism is more common in women, atrial fibrillation is more common among men with thyrotoxicosis, and increases in both sexes with advancing age.538 Atrial fibrillation was reported to occur in more than 25% of thyrotoxic individuals older than 60 years.538 The prevalence might be falling because hyperthyroidism is diagnosed now at an earlier stage in its natural history.539 In general, atrial fibrillation is a major risk factor for thromboembolism, especially stroke.537,540 About 6% of individuals with thyrotoxicosis and atrial fibrillation have been reported to suffer stroke or transient cerebral ischemia before the thyrotoxicosis is controlled; this is about the same as the risk of cerebral embolism in patients with other causes of atrial fibrillation.540 It is difficult to estimate the true risk of thromboembolism in thyrotoxic atrial fibrillation, because the arrhythmia is more prevalent in older persons, and age is itself strongly linked to the risk of stroke.541 The incidence of thromboembolism is highest among patients over 60 years of age and in those with preexisting rheumatic or hypertensive heart disease.538 Thyrotoxicosis may provoke or aggravate angina pectoris owing to increased heart rate, or augmented myocardial contractility with attendant increased myocardial oxygen demand. Most patients with angina and thyrotoxicosis have coronary atherosclerosis, but occasionally the coronary arteries are normal on angiography.542 In subclinical hyperthyroidism subtle hyperthyroid symptoms might be present.543 There is growing evidence that subclinical hyperthyroidism has important effects on the heart. A major concern is the increased risk of development of atrial fibrillation, especially in patients with TSH less than 0.1 mIU/L.492,536,544 A recent meta-analysis has shown that subclinical hyperthyroidism is associated with increased heart rate, atrial arrhythmias, increased LV mass with marginal concentric remodeling, impaired ventricular relaxation, reduced exercise performance, and increased risk for cardiovascular death.482 Diagnosis A measurement of serum TSH below the limits of detection by a reliable laboratory using “ultrasensitive” immunoradiometric methodology provides good evidence of thyrotoxicosis. The diagnosis can be confirmed by measurement of 11/24/2006 10:58:06 AM en docr in e disor ders a n d the he a rt circulating thyroid hormones. The serum T3 level is probably a more reliable index of thyrotoxicosis than is the T4 level. Owing to the frequency with which disease or drugs alter binding of T4 and T3 to plasma proteins, one should always obtain an estimate of unbound hormone, such as the free T4 index, free T3 index, or T4 by equilibrium dialysis. If the TSH concentration is low, a high value for one of these indices will confirm the diagnosis of thyrotoxicosis. Measurements of total T4 and T3 in the serum may be misleading, since patients with heart disease or other serious illnesses may have decreased peripheral conversion of T4 to T3 and decreased plasma protein binding of both hormones.538 As a result, serum total T3 concentration and sometimes total T4 concentration are reduced. Indeed, a normal serum T3 concentration in a patient with severe cardiac disease suggests that thyrotoxicosis may be present.538 Treatment Management of thyrotoxicosis caused by Graves’ disease or toxic nodular goiter ordinarily begins with treatment with an antithyroid drug, either propylthiouracil or methimazole.538,545 These drugs deplete thyroid stores of T4 and T3 by inhibiting their synthesis. The antithyroid drug should be given for several weeks until a euthyroid state is achieved. For patients with severe cardiac manifestations, such as florid CHF, tachyarrhythmia, or unstable angina, more rapid control may be obtained by concurrent treatment with inorganic iodide, which blocks the secretion of thyroid hormones. Methimazole or propylthiouracil should be given before administration of iodide, to prevent conversion of the iodide to thyroid hormone. After a few days the iodide can be discontinued and the patient can be maintained on the antithyroid drug. After the patient has been rendered euthyroid with antithyroid drugs, definitive therapy should be undertaken. For patients with Graves’ disease and major cardiac problems, thyroidal ablation with radioactive iodine is a preferred defi nitive therapy.538 The antithyroid drug may be resumed several days after administration of radioactive iodine for continued control of symptoms. Ordinarily, several weeks are required for a dose of radioactive iodine to exert its full therapeutic effect. In some patients with Graves’ disease, a prolonged course of antithyroid drug may induce spontaneous remission.545 Surgery is an acceptable alternative therapy for some patients with Graves’ disease and is often the preferred form of defi nitive treatment of toxic nodular goiter. After either radioactive iodine or surgery, hypothyroidism often ensues, eventually requiring treatment with T4. Treatment of subclinical hyperthyroidism is to some degree controversial due to the lack of defi nitive data.492,500,501 There is limited evidence that treatment may facilitate spontaneous reversion or cardioversion of atrial fibrillation to sinus rhythm.546 In the case of exogenous subclinical hyperthyroidism, decreasing the levothyroxine dose normalizes the heart rate and results in a nonsignificant reduction of LVEF.547 Beta-blockers decrease atrial premature beats, LV mass index, and impaired diastolic filling.548 Management of amiodarone-induced thyrotoxicosis is an especially vexing problem, for several reasons: (1) hyperthy- CAR108.indd 2313 2 313 roidism can exacerbate the patient’s underlying problem with tachyarrhythmias; (2) antithyroid drugs and 131I are frequently ineffective; (3) the operative risk of thyroidectomy is often high, owing to underlying ischemic heart disease; and (4) amiodarone is an antiarrhythmic drug of last resort, so its discontinuation may be dangerous. Amiodarone-induced thyrotoxicosis usually appears after months or years of administration of the drug.549 There appear to be at least two mechanisms for development of thyrotoxicosis550 : (1) flooding of iodide into an abnormal gland that has lost its ability to suppress thyroxine production in response to an iodide load; and (2) induction of thyroiditis in a previously normal gland. The former variety of amiodarone-induced thyrotoxicosis may be treated with potassium perchlorate together with antithyroid drugs. Patients with amiodarone-induced thyroiditis have been reported to respond to treatment with glucocorticoids.549 The management of CHF with thyrotoxicosis includes reducing volume overload with a diuretic, such as IV furosemide, and providing control of the heart rate when rapid atrial fibrillation exists. Digoxin or another cardiac glycoside can be given to slow the rapid ventricular rate, but in the hyperthyroid patient larger doses than usual are often required. This relative resistance has been attributed to increased clearance of the digoxin, but it may also be due to the need to inhibit the increased number of Na,K-ATPase transport units in cardiac muscle. β-adrenergic blockers such as propranolol help to control heart rate and may be useful, especially in patients without CHF. In the patient with CHF, consideration of using a beta-blocker should be carefully reviewed, since such agents may exacerbate heart failure. The decision as to whether to use the agent in a patient with CHF should be based on the extent to which increased heart rate or high-output state is believed to be the cause of the CHF. Esmolol, a rapidly acting beta-blocker, can be given IV to allow one to determine potential beneficial or detrimental effects of beta-blocking agents in such patients.551 As an alternative to a beta-blocking agent, a slow calcium channel blocker, such as diltiazem or verapamil, can be used to help control heart rate, although the important negative inotropic action of verapamil must be kept in mind. Treatment of atrial fibrillation in patients with thyrotoxicosis should be directed at controlling the ventricular rate with cardiac glycosides and often with betablockers or the calcium antagonists diltiazem or verapamil. Successful cardioversion with maintenance of sinus rhythm usually cannot be achieved as long as the thyrotoxicosis continues. Spontaneous reversion of the rhythm to sinus usually occurs within 6 weeks after the return of the euthyroid state, although atrial fibrillation may persist in some older patients. One should consider the use of anticoagulant therapy in a patient with hyperthyroidism and atrial fibrillation. Anticoagulant therapy with warfarin reduces the frequency of embolic events in some patients with atrial fibrillation, but it is associated with an increased risk for hemorrhage. Nevertheless, we recommend anticoagulation for patients with atrial fibrillation and thyrotoxicosis with a dilated heart or heart failure and for those whose rhythm alternates between sinus rhythm and atrial fibrillation. 11/24/2006 10:58:06 AM 2 314 chapter Carcinoid Syndrome Carcinoid tumors are uncommon neuroendocrine malignancies with an estimated incidence of two to three cases per 100,000 people per year.552,553 More often, these tumors are found incidentally at autopsy.554 Carcinoids arise from enterochromaffin cells, which are widely distributed throughout the body. Approximately 70% of all carcinoid tumors are located in the digestive system, most often in the terminal ileum, appendix or rectum.552,555 The bronchial tree is the second most frequent location.552 The most malignant carcinoid tumors tend to arise from the terminal ileum. Pathophysiology Enterochromaffin cells, together with other neuroendocrine cells in the thyroid, lung, pancreas, pituitary, and adrenal medulla, constitute the amine precursor uptake and decarboxylation (APUD) system described by Pearse.556 Depending on their site of origin, carcinoid tumors can have the ability to secrete vasoactive amino acids and peptides. Serotonin (5-hydroxytryptamine, 5-HT) is the most prominent secretory product. Once released, serotonin is metabolized by monoamine oxidases in the liver, lungs and brain to 5hydroxyindoleacetic acid (5-HIAA).557 However, 5-hydroxytryptophan, bradykinins, histamine, substance P, ACTH, and several other peptides can also be produced by carcinoids.558,559 10 8 right-sided chambers and of the pulmonic and tricuspid valves, as well as the great veins and coronary sinuses (Fig. 108.4). These lesions contain cells embedded in a collagenous stroma, which is rich in glycosaminoglycans but devoid of elastic fibers.566,567 The secretory product responsible for development of these lesions may well be serotonin itself. There are correlations between the presence and severity of cardiac valvular lesions and levels of circulating serotonin565 as well as excretion of 5–HIAA.557,568 Additionally, treatment of obesity with the serotonin reuptake inhibitors fenfluramine and dexfenfluramine has been found to be associated with an increased risk of development of valvular regurgitation, especially of the aortic valve.569–571 Examination of the affected valves has shown lesions similar to those of the carcinoid syndrome, further strengthening the association between serotonin and valvular disease.572 Clinical Manifestations Carcinoid tumors are relatively slow growing. Even with metastatic disease, patients can survive for several years. Unless the secretory products are released directly into the systemic circulation, symptoms are usually not present. The carcinoid syndrome develops in about 50% of patients, principally those with liver metastases or bronchial carcinoids, owing to bypass of first-pass hepatic inactivation of secretory products. The most common clinical elements of the carcinoid syndrome are diarrhea and cutaneous flushes.559,560 Wheezing occurs in a few patients, principally those with bronchial carcinoid. Other endocrine manifestations, such as the ectopic ACTH syndrome, may also be present. Pellagra with dermatitis of sun-exposed areas may also be seen, secondary to the high turnover of nicotinic acid by the tumor. It has not been possible to attribute particular symptoms to specific secretory products, with the exception of diarrhea, which appears related to serotonin.561,562 Rectal carcinoids do not exhibit secretory activity and do not produce the syndrome. The severity of the syndrome is generally correlated with the metastatic tumor burden.560 Carcinoid crisis with severe flushes, diarrhea leading to dehydration, hypotension, and arrhythmias is a potential life threatening complication. It may be provoked by administration of anesthetics during invasive procedures. One of the striking endocrine manifestations of the carcinoid syndrome involves the heart. It occurs in 20% to 70% of patients with metastatic carcinoid tumors.563–565 The typical pathologic lesions are spherical white plaques, attached to the luminal surface of the endocardium of the CAR108.indd 2314 A B FIGURE 108.4. (A) View of opened tricuspid valve from a patient with carcinoid syndrome, showing thickening and contraction of leaflets and chordae tendineae, and thickening of the atrial endocardium. (B) View of opened pulmonic valve from the same patient, showing thickened and retracted cusps and constriction of the valvular ring. 11/24/2006 10:58:07 AM en docr in e disor ders a n d the he a rt The manifestations of carcinoid heart disease are those typical of tricuspid or pulmonic regurgitation, and pulmonic outflow obstruction.565,573 Signs and symptoms are those of RV failure secondary to severe dysfunction of tricuspid and pulmonary valves. Clinical features are often subtle early in the disease course (fatigue, exertional dyspnea) and might be attributed to the primary carcinoid disease. Carcinoid patients may also have labile blood pressure with either pronounced hypotension or hypertension, owing to the presence of vasoactive substances in the circulation. Serotonin can lead to tachycardia and hypertensive crisis refractory to conventional treatment.563 Left-sided carcinoid heart disease may be present in patients with extensive liver metastases, patent foramen ovale, or bronchial or ovarian carcinoids.574– 576 Cardiac metastases of carcinoid tumors are mainly intramyocardial but are extremely rare.577 Diagnosis For patients with suspected carcinoid syndrome, the diagnosis can best be confirmed by measurement of excretion of metabolites of serotonin in 24–hour urine collections. For diagnostic purposes, the most important metabolite is 5HIAA.560 The specificity of this determination is almost 100% but the sensitivity is reported to be much lower— 35%.578 Urinary 5-HIAA levels can be influenced by food (e. g., bananas, pineapple) or medications.579 The platelet serotonin concentration might be a more sensitive marker of serotonin excess.580,581 Serum chromogranin A, an acidic protein present in the chromaffin granules of neuroendocrine cells, can be used for the detection of functioning as well as nonfunctioning tumors. It offers higher sensitivity but the specificity is lower than urinary 5-HIAA.578 Imaging techniques for localization of carcinoid tumors include 111indium-pentreotide scintigraphy and 131I-MIBG scintigraphy, each with sensitivity of 80% to 90%.582 Combination of these tests increases the sensitivity to 95%.582 111 Indium-pentreotide is a labeled analogue of octreotide with affinity for somatostatin receptors located on the cell membranes of carcinoid tumors. A positive fi nding with this compound predicts response to octreotide therapy.583 131I-MIBG is an analogue of biogenic amine precursors that is taken up by chromaffin cells and stored in the neurosecretory granules. Larger doses of this compound have been used for treatment of metastatic carcinoid tumors. Positron emission tomography with [18F]-fluorodihydroxyphenylalanine (18F-DOPA) is a new imaging technique with promising results.584 Computed tomography scanning can be used for visualization of hepatic and extrahepatic abdominal metastases and mediastinal and pulmonary disease.558,585 Primary tumors in the small bowel can be demonstrated with barium follow through, although small tumors can easily be missed. Transthoracic echocardiography remains the cornerstone of diagnosis of cardiac involvement. Right atrial and ventricular enlargement is present in up to 90% of patients with carcinoid heart disease, and ventricular septal wall motion abnormalities are seen in almost half of the cases.573 The tricuspid valve leaflets and subvalvular structures are often thickened and retracted, leading to moderate or severe tricuspid regurgitation.563 Characteristic pulmonary valve involvement includes immobility of the pulmonary valve leaflets. CAR108.indd 2315 2 315 Pulmonary annular constriction may also occur, resulting in predominant pulmonary outflow tract obstruction.586 A new development is the measurement of serum natriuretic peptides for early detection of myocardial damage.587 Treatment Treatment of carcinoid tumors usually involves surgical removal of accessible tumor, with removal, chemoembolization, or radiofrequency ablation of hepatic metastases when feasible.555,558,560 Diarrhea can sometimes be controlled with relatively nonspecific medications such as loperamide and codeine.558 Supplementation of vitamins and nicotinic acid is recommended.558 Flushes can be reduced by avoiding stress and foods known to provoke them.558 An important recent advance has been the introduction of the somatostatin analogues octreotide and lanreotide, which control both diarrhea and flushing.588,589 They have also been reported to inhibit tumor growth, but reduction in tumor volume is only occasionally observed. Octreotide is administered subcutaneously two to four times daily, whereas lanreotide can be injected less frequently. Long-acting analogues of octreotide are now available. The principal side effects of somatostatin analogues include malabsorption, hypomotility of the gallbladder and formation of gallstones, and mild glucose intolerance.555 Intravenous octreotide can be used for the preoperative prevention and treatment of carcinoid crisis.590 Interferon-α has been reported to induce biochemical response in 40% of patients.555,558 In general, carcinoid tumors are poorly responsive to standard antineoplastic drugs.558,560 Patients with carcinoid heart disease frequently die as a result of severe tricuspid regurgitation rather than carcinomatosis.563 In one series mean life expectancy was 1.6 years for patients with carcinoid heart disease and 4.6 years in those without cardiac damage.591 Therefore, consideration should be given to the suitability of a patient for valvular surgery even with metastatic disease. It is usually considered preferable to operate early or soon after the onset of cardiac symptoms, as delay can result in worsening of the right ventricular failure and increase the risk of surgery.563,586 Although surgical mortality is high, there is evidence to support an increase in longevity and quality of life after successful surgery.592,593 Summary There is increased mortality from cardiovascular disease among adults with hypopituitarism, perhaps related to growth hormone deficiency, which has been linked to known cardiovascular risk factors. Acromegaly is associated with cardiomegaly, cardiac hypertrophy, hypertension, congestive heart failure, coronary artery disease, and arrhythmias. Successful treatment of acromegaly abolishes the excess mortality associated with the disease. Arterial hypotension is the most common cardiovascular finding in adrenal insufficiency. Acute adrenal crisis should be treated with “stress” doses of intravenous hydrocortisone. Chronic adrenal insufficiency may require treatment with mineralocorticoids as well as glucocorticoids. 11/24/2006 10:58:07 AM 2 316 chapter The major cardiovascular abnormalities of Cushing’s syndrome are hypertension, myocardial hypertrophy, and a prothrombotic state. Hyperaldosteronism is more commonly linked to hypertension than was previously appreciated. Hypokalemia is an important complication of hyperaldosteronism, but most patients are normokalemic. There are mineralocorticoid receptors in the heart, and treatment with mineralocorticoid antagonists can benefit individuals following myocardial infarction as well as those with congestive heart failure. Pheochromocytoma is an uncommon cause of hypertension, but has been found in 4% of individuals with adrenal nodules and hypertension. Once the diagnosis is made, pharmacologic therapy should be started promptly, before invasive procedures or surgery are attempted. The “metabolic syndrome” is a constellation of metabolic and constitutional abnormalities that includes obesity, insulin resistance, dyslipidemia, hypertension, and prothrombotic and proinflammatory states. This syndrome carries a high risk for development of atherosclerotic disease and type 2 diabetes mellitus. There is increased cardiovascular mortality among individuals with diabetes mellitus. Aggressive treatment of multiple risk factors, including hyperglycemia, hypertension, and dyslipidemia, can prevent cardiovascular events. For critically ill individuals in the hospital, intensive treatment of hyperglycemia reduces mortality. Patients with primary hyperparathyroidism have excess cardiovascular mortality. Patients with nonthyroidal illness have low circulating thyroid hormone levels without elevation of TSH, known as the “euthyroid sick” syndrome. Treatment of this syndrome with thyroid hormone does not improve outcomes. The major cardiovascular fi ndings of hypothyroidism are bradycardia, cardiac enlargement, hypertension, low voltage on the ECG, and sometimes pericardial effusion. “Subclinical hypothyroidism” is associated with increased lipids and cardiac functional abnormalities, but has not yet been conclusively linked to excess cardiovascular events. Both overt and subclinical hyperthyroidism are linked to atrial fibrillation, especially in older individuals. The major clinical cardiovascular manifestations of carcinoid syndrome are those of pulmonic regurgitation or stenosis, or tricuspid regurgitation, related to the presence of endocardial plaques, principally on the right side of the heart. Acknowledgment We thank Dr. Carlos Hamilton Jr. for his helpful suggestions. References 1. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157–198. 2. Day SM, Gu J, Polak JM, et al. Somatostatin in the human heart and comparison with guinea pig and rat heart. Br Heart J 1985;53:153–157. 3. Eryol NK, Guven M, Topsakal R, et al. The effects of octreotide in dilated cardiomyopathy: an open-label trial in 12 patients. Jpn Heart J 2004;45:613–621. CAR108.indd 2316 10 8 4. Gunal AI, Isik A, Celiker H, et al. Short term reduction of left ventricular mass in primary hypertrophic cardiomyopathy by octreotide injections. Heart 1996;76:418–421. 5. Wallaschofski H, Donne M, Eigenthaler M, et al. PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab 2001;86:5912–5919. 6. Wallaschofski H, Kobsar A, Koksch M, et al. Prolactin receptor signaling during platelet activation. Horm Metab Res 2003; 35:228–235. 7. McCallum RW, Petrie JR, Dominiczak AF, et al. Growth hormone deficiency and vascular risk. Clin Endocrinol (Oxf) 2002;57:11–24. 8. Bates AS, Van’t Hoff W, Jones PJ, et al. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996; 81:1169–1172. 9. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285–288. 10. de Boer H, Blok GJ, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocr Rev 1995;16:63–86. 11. Colao A, Vitale G, Pivonello R, et al. The heart: an end-organ of GH action. Eur J Endocrinol 2004;151(suppl 1):S93–101. 12. Carroll PV, Christ ER, Bengtsson BA, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998;83:382–395. 13. Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994;15:555–573. 14. Shalet SM, Toogood A, Rahim A, et al. The diagnosis of growth hormone deficiency in children and adults. Endocr Rev 1998; 19:203–223. 15. Aimaretti G, Corneli G, Razzore P, et al. Comparison between insulin-induced hypoglycemia and growth hormone (GH)releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J Clin Endocrinol Metab 1998;83:1615–1618. 16. Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 2003;108:2648–2652. 17. Elgzyri T, Castenfors J, Hagg E, et al. The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency. Clin Endocrinol (Oxf) 2004;61:113–122. 18. Colao A, di Somma C, Pivonello R, et al. The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. J Clin Endocrinol Metab 2002;87:1088–1093. 19. Melmed S. Acromegaly. N Engl J Med 1990;322:966–977. 20. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev 1991;12: 424–449. 21. Klapper DG, Svoboda ME, Van Wyk JJ. Sequence analysis of somatomedin-C: confi rmation of identity with insulin-like growth factor I. Endocrinology 1983;112:2215–2217. 22. LeRoith D, Werner H, Beitner-Johnson D, et al. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995;16:143–163. 23. Le Roith D, Butler AA. Insulin-like growth factors in pediatric health and disease. J Clin Endocrinol Metab 1999;84:4355– 4361. 24. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978;253:2769–2776. 25. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989;10:68–91. 26. Isaksson O. GH, IGF-I, and growth. J Pediatr Endocrinol Metab 2004;17(suppl 4):1321–1326. 11/24/2006 10:58:07 AM en docr in e disor ders a n d the he a rt 27. Davidson MB. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 1987;8:115–131. 28. Thuesen L, Christiansen JS, Sorensen KE, et al. Increased myocardial contractility following growth hormone administration in normal man. An echocardiographic study. Dan Med Bull 1988;35:193–196. 29. Ezzat S, Melmed S. Clinical review 18: Are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 1991;72:245–249. 30. Ezzat S, Strom C, Melmed S. Colon polyps in acromegaly. Ann Intern Med 1991;114:754–755. 31. Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83:2730–2734. 32. McGuffi n WL Jr, Sherman BM, Roth F, et al. Acromegaly and cardiovascular disorders. A prospective study. Ann Intern Med 1974;81:11–18. 33. Baldwin A, Cundy T, Butler J, et al. Progression of cardiovascular disease in acromegalic patients treated by external pituitary irradiation. Acta Endocrinol (Copenh) 1985;108: 26–30. 34. Lie JT. Pathology of the heart in acromegaly: anatomic fi ndings in 27 autopsied patients. Am Heart J 1980;100:41–52. 35. Mather HM, Boyd MJ, Jenkins JS. Heart size and function in acromegaly. Br Heart J 1979;41:697–701. 36. Csanady M, Gaspar L, Hogye M, et al. The heart in acromegaly: an echocardiographic study. Int J Cardiol 1983;2:349–361. 37. Rossi L, Thiene G, Caragaro L, et al. Dysrhythmias and sudden death in acromegalic heart disease. A clinicopathologic study. Chest 1977;72:495–498. 38. Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004;25:102–152. 39. Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 1992;21:597–614. 40. Souadjian JV, Schirger A. Hypertension in acromegaly. Am J Med Sci 1967;254:629–633. 41. Moore TJ, Thein-Wai W, Dluhy RG, et al. Abnormal adrenal and vascular responses to angiotensin II and an angiotensin antagonist in acromegaly. J Clin Endocrinol Metab 1980;51: 215–222. 42. Cain JP, Williams GH, Dluhy RG. Plasma renin activity and aldosterone secretion in patients with acromegaly. J Clin Endocrinol Metab 1972;34:73–81. 43. Snow MH, Piercy DA, Robson V, et al. An investigation into the pathogenesis of hypertension in acromegaly. Clin Sci Mol Med 1977;53:87–91. 44. Ogihara T, Hata T, Maruyama A, et al. Blood pressure response to an angiotensin II antagonist in patients with acromegaly. J Clin Endocrinol Metab 1979;48:159–162. 45. Colao A, Marzullo P, Di Somma C, et al. Growth hormone and the heart. Clin Endocrinol (Oxf) 2001;54:137–154. 46. Clayton RN. Cardiovascular function in acromegaly. Endocr Rev 2003;24:272–277. 47. Stewart PM, Smith S, Seth J, et al. Normal growth hormone response to the 75 g oral glucose tolerance test measured by immunoradiometric assay. Ann Clin Biochem 1989;26(pt 2): 205–206. 48. Freda PU. Current concepts in the biochemical assessment of the patient with acromegaly. Growth Horm IGF Res 2003;13: 171–184. 49. Chang-DeMoranville BM, Jackson IM. Diagnosis and endocrine testing in acromegaly. Endocrinol Metab Clin North Am 1992;21:649–668. 50. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference CAR108.indd 2317 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 2 317 of the Growth Hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab 2004;89:3099–3102. Swearingen B, Barker FG, 2nd, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419–3426. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89: 667–674. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526–529. Melmed S, Jackson I, Kleinberg D, et al. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 1998;83: 2646–2652. Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87: 4054–4058. Clemmons DR, Chihara K, Freda PU, et al. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 2003;88:4759–4767. Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 1992;117:711–718. Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 1992;117:719–726. Ayuk J, Stewart SE, Stewart PM, et al. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 2002;87:4142– 4146. Ayuk J, Stewart SE, Stewart PM, et al. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol (Oxf) 2004;60: 375–381. Muller AF, Kopchick JJ, Flyvbjerg A, et al. Clinical review 166: Growth hormone receptor antagonists. J Clin Endocrinol Metab 2004;89:1503–1511. Williams GH, Braunwald E. Endocrine and nutritional disorders and heart disease. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders, 1992:1827–1830. Molitch M. Acromegaly. In: Collu R, Brown GM, Vanloon GR, eds. Clinical Neuroendocrinology. Boston: Blackwell Scientific Publications, 1988:189–227. Oelkers W. Adrenal insufficiency. N Engl J Med 1996;335: 1206–1212. Knowlton AI, Baer L. Cardiac failure in Addison’s disease. Am J Med 1983;74:829–836. Fallo F, Betterle C, Budano S, et al. Regression of cardiac abnormalities after replacement therapy in Addison’s disease. Eur J Endocrinol 1999;140:425–428. Eto K, Koga T, Sakamoto A, et al. Adult reversible cardiomyopathy with pituitary adrenal insufficiency caused by empty sella—a case report. Angiology 2000;51:319–323. Afzal A, Khaja F. Reversible cardiomyopathy associated with Addison’s disease. Can J Cardiol 2000;16:377–379. May ME, Carey RM. Rapid adrenocorticotropic hormone test in practice. Retrospective review. Am J Med 1985;79:679–684. Thaler LM, Blevins LS Jr. The low dose (1–microg) adrenocorticotropin stimulation test in the evaluation of patients with suspected central adrenal insufficiency. J Clin Endocrinol Metab 1998;83:2726–2729. Rose LI, Williams GH, Jagger PI, et al. The 48–hour adrenocorticotrophin infusion test for adrenocortical insufficiency. Ann Intern Med 1970;73:49–54. 11/24/2006 10:58:07 AM 2 318 chapter 72. Conwell LS, Gray LM, Delbridge RG, et al. Reversible cardiomyopathy in paediatric Addison’s disease—a cautionary tale. J Pediatr Endocrinol Metab 2003;16:1191–1195. 73. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932;50:137. 74. Baid S, Nieman LK. Glucocorticoid excess and hypertension. Curr Hypertens Rep 2004;6:493–499. 75. Tauchmanova L, Rossi R, Biondi B, et al. Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002;87:4872– 4878. 76. Saruta T, Suzuki H, Handa M, et al. Multiple factors contribute to the pathogenesis of hypertension in Cushing’s syndrome. J Clin Endocrinol Metab 1986;62:275–279. 77. Munakata M, Imai Y, Abe K, et al. Involvement of the hypothalamo-pituitary-adrenal axis in the control of circadian blood pressure rhythm. J Hypertens Suppl 1988;6:S44–46. 78. Piovesan A, Panarelli M, Terzolo M, et al. 24–hour profiles of blood pressure and heart rate in Cushing’s syndrome: relationship between cortisol and cardiovascular rhythmicities. Chronobiol Int 1990;7:263–265. 79. Zelinka T, Strauch B, Pecen L, et al. Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing’s syndrome. J Hum Hypertens 2004;18:107–111. 80. Fallo F, Budano S, Sonino N, et al. Left ventricular structural characteristics in Cushing’s syndrome. J Hum Hypertens 1994;8:509–513. 81. Muiesan ML, Lupia M, Salvetti M, et al. Left ventricular structural and functional characteristics in Cushing’s syndrome. J Am Coll Cardiol 2003;41:2275–2279. 82. Sugihara N, Shimizu M, Kita Y, et al. Cardiac characteristics and postoperative courses in Cushing’s syndrome. Am J Cardiol 1992;69:1475–1480. 83. Krieger DT. Physiopathology of Cushing’s disease. Endocr Rev 1983;4:22–43. 84. Boscaro M, Sonino N, Scarda A, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome. J Clin Endocrinol Metab 2002;87:3662–3626. 85. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001;86:4041–4046. 86. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88:5593–5602. 87. Nieman LK. Diagnostic tests for Cushing’s syndrome. Ann N Y Acad Sci 2002;970:112–118. 88. Yanovski JA, Cutler GB Jr, Chrousos GP, et al. Corticotropinreleasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing’s syndrome from pseudo-Cushing’s states. JAMA 1993;269: 2232–2238. 89. Kaye TB, Crapo L. The Cushing syndrome: an update on diagnostic tests. Ann Intern Med 1990;112:434–444. 90. Loriaux DL, Nieman L. Corticotropin-releasing hormone testing in pituitary disease. Endocrinol Metab Clin North Am 1991;20:363–369. 91. Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing’s syndrome. N Engl J Med 1991;325:897–905. 92. Boggan JE, Tyrrell JB, Wilson CB. Transsphenoidal microsurgical management of Cushing’s disease. Report of 100 cases. J Neurosurg 1983;59:195–200. 93. Nolan PM, Sheeler LR, Hahn JF, et al. Therapeutic problems with transsphenoidal pituitary surgery for Cushing’s disease. Cleve Clin Q 1982;49:199–207. CAR108.indd 2318 10 8 94. Olivieri O, Ciacciarelli A, Signorelli D, et al. Aldosterone to renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 2004;89:4221–4226. 95. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004;89:1045–1050. 96. White PC. Disorders of aldosterone biosynthesis and action. N Engl J Med 1994;331:250–258. 97. Blumenfeld JD, Sealey JE, Schlussel Y, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994;121:877–885. 98. White PC, Speiser PW. Steroid 11 beta-hydroxylase deficiency and related disorders. Endocrinol Metab Clin North Am 1994; 23:325–339. 99. Kater CE, Biglieri EG. Disorders of steroid 17 alpha-hydroxylase deficiency. Endocrinol Metab Clin North Am 1994;23:341–357. 100. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism. Endocrinol Metab Clin North Am 1994;23:285–297. 101. Walker BR, Edwards CR. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metab Clin North Am 1994;23:359–377. 102. Shimkets RA, Warnock DG, Bositis CM, et al. Liddle’s syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994; 79:407–414. 103. Krozowski ZS, Provencher PH, Smith RE, et al. Isozymes of 11 beta-hydroxysteroid dehydrogenase: which enzyme endows mineralocorticoid specificity? Steroids 1994;59:116–120. 104. White PC, Mune T, Agarwal AK. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 1997;18:135–156. 105. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25: 563–575. 106. Young M, Fullerton M, Dilley R, et al. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994;93:2578– 2583. 107. Struthers AD. Aldosterone blockade in cardiovascular disease. Heart 2004;90:1229–1234. 108. Stowasser M, Gordon RD. Primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2003;17:591–605. 109. Montori VM, Young WF Jr. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 2002;31:619–632, xi. 110. Kater CE, Biglieri EG, Brust N, et al. Stimulation and suppression of the mineralocorticoid hormones in normal subjects and adrenocortical disorders. Endocr Rev 1989;10:149–164. 111. Young WF Jr. Pheochromocytoma and primary aldosteronism: diagnostic approaches. Endocrinol Metab Clin North Am 1997; 26:801–827. 112. Bravo EL. Primary aldosteronism. Issues in diagnosis and management. Endocrinol Metab Clin North Am 1994;23:271–283. 113. Espiner EA, Ross DG, Yandle TG, et al. Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling. J Clin Endocrinol Metab 2003;88:3637–3644. 114. Young WF Jr. Minireview: primary aldosteronism—changing concepts in diagnosis and treatment. Endocrinology 2003;144: 2208–2213. 115. Sawka AM, Young WF, Thompson GB, et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001;135:258–261. 116. Celen O, O’Brien MJ, Melby JC, et al. Factors influencing outcome of surgery for primary aldosteronism. Arch Surg 1996;131:646–650. 11/24/2006 10:58:08 AM en docr in e disor ders a n d the he a rt 117. Rose LI, Underwood RH, Newmark SR, et al. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med 1977;87:398–403. 118. Weinberger MH. Eplerenone: a new selective aldosterone receptor antagonist. Drugs Today (Barc) 2004;40:481–485. 119. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–717. 120. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309– 1321. 121. Tan LB, Schlosshan D, Barker D. Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy. Int J Cardiol 2004;96:321–333. 122. Meier DJ, Pitt B, Rajagopalan S. Eplerenone: will it have a role in the treatment of acute coronary syndromes? Curr Cardiol Rep 2004;6:259–263. 123. Davis KL, Nappi JM. The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist. Clin Ther 2003;25:2647–2668. 124. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543–551. 125. Wurtman RJ, Axelrod J. Control of enzymatic synthesis of adrenaline in the adrenal medulla by adrenal cortical steroids. J Biol Chem 1966;241:2301–2305. 126. McNeil AR, Blok BH, Koelmeyer TD, et al. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med 2000;30:648–652. 127. Smythe GA, Edwards G, Graham P, et al. Biochemical diagnosis of pheochromocytoma by simultaneous measurement of urinary excretion of epinephrine and norepinephrine. Clin Chem 1992;38:486–492. 128. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000;85:637–644. 129. Baguet JP, Hammer L, Mazzuco TL, et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol 2004;150:681– 686. 130. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 2003;24:539–553. 131. Goldstein RE, O’Neill JA Jr, Holcomb GW 3rd, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999;229:755–764; discussion 764–766. 132. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459–1466. 133. Steiner AL, Goodman AD, Powers SR. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing’s disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore) 1968;47:371–409. 134. Khairi MR, Dexter RN, Burzynski NJ, et al. Mucosal neuroma, pheochromocytoma and medullary thyroid carcinoma: multiple endocrine neoplasia type 3. Medicine (Baltimore) 1975; 54:89–112. 135. Osranek M, Bursi F, Gura GM, et al. Echocardiographic features of pheochromocytoma of the heart. Am J Cardiol 2003; 91:640–643. 136. Bravo EL, Gifford RW Jr. Current concepts. Pheochromocytoma: diagnosis, localization and management. N Engl J Med 1984;311:1298–1303. 137. Levenson JA, Safar ME, London GM, et al. Haemodynamics in patients with phaeochromocytoma. Clin Sci (Lond) 1980;58: 349–356. CAR108.indd 2319 2 319 138. McManus BM, Fleury TA, Roberts WC. Fatal catecholamine crisis in pheochromocytoma: curable cause of cardiac arrest. Am Heart J 1981;102:930–932. 139. Cueto L, Arriaga J, Zinser J. Echocardiographic changes in pheochromocytoma. Chest 1979;76:600–601. 140. Shub C, Cueto-Garcia L, Sheps SG, et al. Echocardiographic fi ndings in pheochromocytoma. Am J Cardiol 1986;57:971– 975. 141. Brilakis ES, Young WF Jr, Wilson JW, et al. Reversible catecholamine-induced cardiomyopathy in a heart transplant candidate without persistent or paroxysmal hypertension. J Heart Lung Transplant 1999;18:376–380. 142. Dalby MC, Burke M, Radley-Smith R, et al. Pheochromocytoma presenting after cardiac transplantation for dilated cardiomyopathy. J Heart Lung Transplant 2001;20:773–775. 143. Imperato-McGinley J, Gautier T, Ehlers K, et al. Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma. N Engl J Med 1987;316:793–797. 144. Goldstein DS, Eisenhofer G, Flynn JA, et al. Diagnosis and localization of pheochromocytoma. Hypertension 2004;43: 907–910. 145. Van Vliet PD, Burchell HB, Titus JL. Focal myocarditis associated with pheochromocytoma. N Engl J Med 1966;274:1102– 1108. 146. Scott I, Parkes R, Cameron DP. Phaeochromocytoma and cardiomyopathy. Med J Aust 1988;148:94–96. 147. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002;287: 1427–1434. 148. Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003;88: 2656–2666. 149. Pacak K, Linehan WM, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001;134:315–329. 150. Mannelli M, Ianni L, Cilotti A, et al. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 1999; 141:619–624. 151. Francis IR, Korobkin M. Pheochromocytoma. Radiol Clin North Am 1996;34:1101–1112. 152. Maurea S, Cuocolo A, Reynolds JC, et al. Iodine-131–metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med 1993;34:173–179. 153. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 2004;89:479–491. 154. van der Harst E, de Herder WW, Bruining HA, et al. [(123)I]me taiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685–693. 155. Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999;43:217– 223. 156. Limouris GS, Giannakopoulos V, Stavraka A, et al. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mIBG scintimaging in neural crest tumors. Anticancer Res 1997;17: 1589–1592. 157. Pacak K, Eisenhofer G, Carrasquillo JA, et al. 6– [18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001;38:6–8. 158. Ilias I, Yu J, Carrasquillo JA, et al. Superiority of 6-[18F]fluorodopamine positron emission tomography versus [131I]metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 2003;88:4083–4087. 11/24/2006 10:58:08 AM 2320 chapter 159. Hoffman B. Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists. In: Hardman JG, Lombard LE, eds. Goodman and Gillman’s The Pharmacological Basis of Therapeutics. Philadelphia: McGaw-Hill, 2001:215–268. 160. Bravo EL. Pheochromocytoma: an approach to antihypertensive management. Ann N Y Acad Sci 2002;970:1–10. 161. Serfas D, Shoback DM, Lorell BH. Phaeochromocytoma and hypertrophic cardiomyopathy: apparent suppression of symptoms and noradrenaline secretion by calcium-channel blockade. Lancet 1983;2:711–713. 162. Lehmann HU, Hochrein H, Witt E, et al. Hemodynamic effects of calcium antagonists. Review. Hypertension 1983;5: II66–73. 163. Nerup J, Mandrup-Poulsen T, Molvig J, et al. Mechanisms of pancreatic beta-cell destruction in type I diabetes. Diabetes Care 1988;11(suppl 1):16–23. 164. Cahill GF Jr, McDevitt HO. Insulin-dependent diabetes mellitus: the initial lesion. N Engl J Med 1981;304:1454–1465. 165. Atkinson MA, Maclaren NK. The pathogenesis of insulindependent diabetes mellitus. N Engl J Med 1994;331:1428– 1436. 166. Todd JA, Bell JI, McDevitt HO. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987;329:599–604. 167. Barnett AH, Eff C, Leslie RD, et al. Diabetes in identical twins. A study of 200 pairs. Diabetologia 1981;20:87–93. 168. Nerup J, Mandrup-Poulsen T, Molvig J. The HLA-IDDM association: implications for etiology and pathogenesis of IDDM. Diabetes Metab Rev 1987;3:779–802. 169. Christau B, Kromann H, Andersen OO, et al. Incidence, seasonal and geographical patterns of juvenile-onset insulindependent diabetes mellitus in Denmark. Diabetologia 1977;13:281–284. 170. LaPorte RE, Fishbein HA, Drash AL, et al. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) registry. The incidence of insulin-dependent diabetes mellitus in Allegheny County, Pennsylvania (1965–1976). Diabetes 1981;30:279–284. 171. Newman B, Selby JV, King MC, et al. Concordance for type 2 (non-insulin-dependent) diabetes mellitus in male twins. Diabetologia 1987;30:763–768. 172. Harris MI, Klein R, Welborn TA, et al. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 1992;15:815–819. 173. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88:787–835, ix. 174. Dickson LM, Rhodes CJ. Pancreatic beta-cell growth and survival in the onset of type 2 diabetes: a role for protein kinase B in the Akt? Am J Physiol Endocrinol Metab 2004;287: E192–198. 175. Bouche C, Serdy S, Kahn CR, et al. The cellular fate of glucose and its relevance in type 2 diabetes. Endocr Rev 2004;25:807– 830. 176. Grundy SM, Hansen B, Smith SC Jr, et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004;109:551–556. 177. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414–419. 178. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391–397. 179. Alexander CM, Landsman PB, Teutsch SM, et al. NCEP-defi ned metabolic syndrome, diabetes, and prevalence of coronary CAR108.indd 2320 10 8 heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210–1214. 180. Ritchie SA, Ewart MA, Perry CG, et al. The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci (Lond) 2004;107:519–532. 181. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004;89:447–452. 182. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347–355. 183. Friedman JM. The function of leptin in nutrition, weight, and physiology. Nutr Rev 2002;60:S1–14; discussion S68–84,85–87. 184. Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004;351:987–997. 185. Wolf G. Insulin resistance and obesity: resistin, a hormone secreted by adipose tissue. Nutr Rev 2004;62:389–394. 186. Rea R, Donnelly R. Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity? Diabetes Obes Metab 2004;6:163–170. 187. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003;108:736–740. 188. Goldstein BJ, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004;89:2563–2568. 189. Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24: 29–33. 190. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730–1737. 191. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005307:426–430. 192. Talbott E, Clerici A, Berga SL, et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 1998;51:415–422. 193. Wild S, Pierpoint T, McKeigue P, et al. Cardiovascular disease in women with polycystic ovary syndrome at long-term followup: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52:595–600. 194. Sieminska L, Marek B, Kos-Kudla B, et al. Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters. J Endocrinol Invest 2004;27:528–534. 195. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20:2414–2421. 196. Talbott EO, Zborowski JV, Rager JR, et al. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:5454– 5461. 197. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 2001;52:401–419. 198. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 2003;14:365–370. 199. Moghetti P, Tosi F, Castello R, et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996;81:952–960. 200. Ganie MA, Khurana ML, Eunice M, et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab 2004;89:2756–2762. 11/24/2006 10:58:08 AM en docr in e disor ders a n d the he a rt 201. Narayan KM, Boyle JP, Thompson TJ, et al. Lifetime risk for diabetes mellitus in the United States. JAMA 2003;290: 1884–1890. 202. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 1984;91:1–9. 203. Tsilibary EC. Microvascular basement membranes in diabetes mellitus. J Pathol 2003;200:537–546. 204. Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2001;109(suppl 2):S424–437. 205. Williamson JR, Kilo C. Capillary basement membranes in diabetes. Diabetes 1983;32(suppl 2):96–100. 206. Factor SM, Okun EM, Minase T. Capillary microaneurysms in the human diabetic heart. N Engl J Med 1980;302:384–388. 207. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–117. 208. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329: 977–986. 209. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837– 853. 210. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854–865. 211. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–393. 212. Klein R, Klein BE, Moss SE. The Wisconsin epidemiological study of diabetic retinopathy: a review. Diabetes Metab Rev 1989;5:559–570. 213. Rosenstock J, Raskin P. Diabetes and its complications: blood glucose control vs. genetic susceptibility. Diabetes Metab Rev 1988;4:417–435. 214. Stern MP. Diabetes and cardiovascular disease. The “common soil” hypothesis. Diabetes 1995;44:369–374. 215. Stern MP. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med 1996;124:110–116. 216. D’Agostino RB Jr, Hamman RF, Karter AJ, et al. Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care 2004;27:2234–2240. 217. Festa A, D’Agostino R Jr, Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002;51:1131–1137. 218. Dunn FL. Hyperlipidemia in diabetes mellitus. Diabetes Metab Rev 1990;6:47–61. 219. Bagdade JD, Porte D Jr, Bierman EL. Diabetic lipemia. A form of acquired fat-induced lipemia. N Engl J Med 1967;276: 427–433. 220. Taskinen MR. Lipoprotein lipase in diabetes. Diabetes Metab Rev 1987;3:551–570. 221. Garg A, Grundy SM. Treatment of dyslipidemia in noninsulin-dependent diabetes mellitus with lovastatin. Am J Cardiol 1988;62:44J–49J. 222. Kissebah AH. Low density lipoprotein metabolism in noninsulin-dependent diabetes mellitus. Diabetes Metab Rev 1987; 3:619–651. CAR108.indd 2321 2 3 21 223. Fisher WR. Heterogeneity of plasma low density lipoproteins manifestations of the physiologic phenomenon in man. Metabolism 1983;32:283–291. 224. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 2004;89:2601–2607. 225. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care 1998;21:1138–1145. 226. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–234. 227. Wei M, Gaskill SP, Haffner SM, et al. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998;21:1167– 1172. 228. Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 1989;14: 49–57. 229. Herlitz J, Malmberg K, Karlson BW, et al. Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction. Acta Med Scand 1988;224:31–38. 230. Abbott RD, Donahue RP, Kannel WB, et al. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA 1988;260:3456– 3460. 231. Nesto RW, Phillips RT, Kett KG, et al. Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy. Ann Intern Med 1988;108:170–175. 232. Roy TM, Peterson HR, Snider HL, et al. Autonomic influence on cardiovascular performance in diabetic subjects. Am J Med 1989;87:382–388. 233. Zola B, Kahn JK, Juni JE, et al. Abnormal cardiac function in diabetic patients with autonomic neuropathy in the absence of ischemic heart disease. J Clin Endocrinol Metab 1986;63: 208–214. 234. Pfeifer MA, Cook D, Brodsky J, et al. Quantitative evaluation of cardiac parasympathetic activity in normal and diabetic man. Diabetes 1982;31:339–345. 235. Ambepityia G, Kopelman PG, Ingram D, et al. Exertional myocardial ischemia in diabetes: a quantitative analysis of anginal perceptual threshold and the influence of autonomic function. J Am Coll Cardiol 1990;15:72–77. 236. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med 1980;49:95–108. 237. Maser RE, Mitchell BD, Vinik AI, et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003;26: 1895–1901. 238. Fein FS, Strobeck JE, Malhotra A, et al. Reversibility of diabetic cardiomyopathy with insulin in rats. Circ Res 1981;49:1251– 1261. 239. Fein FS, Miller-Green B, Zola B, et al. Reversibility of diabetic cardiomyopathy with insulin in rabbits. Am J Physiol 1986;250: H108–113. 240. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29–34. 241. Thuesen L, Christiansen JS, Mogensen CE, et al. Cardiac hyperfunction in insulin-dependent diabetic patients developing microvascular complications. Diabetes 1988;37:851–856. 11/24/2006 10:58:08 AM 2322 chapter 242. Sanderson JE, Brown DJ, Rivellese A, et al. Diabetic cardiomyopathy? An echocardiographic study of young diabetics. Br Med J 1978;1:404–407. 243. Ruddy TD, Shumak SL, Liu PP, et al. The relationship of cardiac diastolic dysfunction to concurrent hormonal and metabolic status in type I diabetes mellitus. J Clin Endocrinol Metab 1988;66:113–118. 244. Crepaldi G, Nosadini R. Diabetic cardiopathy: is it a real entity? Diabetes Metab Rev 1988;4:273–288. 245. Sutherland CG, Fisher BM, Frier BM, et al. Endomyocardial biopsy pathology in insulin-dependent diabetic patients with abnormal ventricular function. Histopathology 1989;14:593– 602. 246. Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30:595–602. 247. Fischer VW, Barner HB, Leskiw ML. Capillary basal laminar thickness in diabetic human myocardium. Diabetes 1979;28: 713–719. 248. Fisher BM, Gillen G, Lindop GB, et al. Cardiac function and coronary arteriography in asymptomatic type 1 (insulin-dependent) diabetic patients: evidence for a specific diabetic heart disease. Diabetologia 1986;29:706–712. 249. Zoneraich S. Diabetes and the Heart. Charles C. Thomas, Springfield, IL: 1978. 250. Regan TJ, Lyons MM, Ahmed SS, et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977;60: 884–899. 251. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med 1996;125:304–310. 252. Fein FS, Capasso JM, Aronson RS, et al. Combined renovascular hypertension and diabetes in rats: a new preparation of congestive cardiomyopathy. Circulation 1984;70:318– 330. 253. Factor SM, Minase T, Cho S, et al. Coronary microvascular abnormalities in the hypertensive-diabetic rat. A primary cause of cardiomyopathy? Am J Pathol 1984;116:9–20. 254. Factor SM, Minase T, Bhan R, et al. Hypertensive diabetic cardiomyopathy in the rat: ultrastructural features. Virchows Arch A Pathol Anat Histopathol 1983;398:305–317. 255. Factor SM, Bhan R, Minase T, et al. Hypertensive-diabetic cardiomyopathy in the rat: an experimental model of human disease. Am J Pathol 1981;102:219–228. 256. Fein FS, Cho S, Malhotra A, et al. Beneficial effects of diltiazem on the natural history of hypertensive diabetic cardiomyopathy in rats. J Am Coll Cardiol 1991;18:1406–1417. 257. Schaffer SW, Mozaffari MS, Artman M, et al. Basis for myocardial mechanical defects associated with non-insulin-dependent diabetes. Am J Physiol 1989;256:E25–30. 258. Borda E, Pascual J, Wald M, et al. Hypersensitivity to calcium associated with an increased sarcolemmal Ca2+-ATPase activity in diabetic rat heart. Can J Cardiol 1988;4:97–101. 259. Afzal N, Ganguly PK, Dhalla KS, et al. Beneficial effects of verapamil in diabetic cardiomyopathy. Diabetes 1988;37:936– 942. 260. Deorari AK, Saxena A, Singh M, et al. Echocardiographic assessment of infants born to diabetic mothers. Arch Dis Child 1989;64:721–724. 261. Nelson RG, Bennett PH, Beck GJ, et al. Development and progression of renal disease in Pima Indians with non-insulindependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996;335:1636–1642. 262. Mauer SM, Steffes MW, Brown DM. The kidney in diabetes. Am J Med 1981;70:603–612. 263. Supplement 1. American Diabetes Association: clinical practice recommendations 2000. Diabetic nephropathy. Diabetes Care 2000;23(suppl 1):S69–72. CAR108.indd 2322 10 8 264. Messent JW, Elliott TG, Hill RD, et al. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int 1992;41:836– 839. 265. Neil A, Hawkins M, Potok M, et al. A prospective populationbased study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993;16:996–1003. 266. Stehouwer CD, Nauta JJ, Zeldenrust GC, et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992;340: 319–323. 267. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356–360. 268. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) 1987;294:1651–1654. 269. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, et al. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 1987;30:144–148. 270. Parving HH. Impact of blood pressure and antihypertensive treatment on incipient and overt nephropathy, retinopathy, and endothelial permeability in diabetes mellitus. Diabetes Care 1991;14:260–269. 271. Rossing P, Hommel E, Smidt UM, et al. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 1993;42:715–719. 272. Viberti GC, Walker JD. Diabetic nephropathy: etiology and prevention. Diabetes Metab Rev 1988;4:147–162. 273. Ravid M, Brosh D, Ravid-Safran D, et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998;158:998–1004. 274. Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia—a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl 1994;45: S125–131. 275. Peripheral arterial disease in people with diabetes. Diabetes Care 2003;26:3333–3341. 276. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 1990;13:513– 521. 277. Jude EB, Oyibo SO, Chalmers N, et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001;24:1433–1437. 278. Teodorescu VJ, Chen C, Morrissey N, et al. Detailed protocol of ischemia and the use of noninvasive vascular laboratory testing in diabetic foot ulcers. Am J Surg 2004;187:75S–80S. 279. Supplement 1. American Diabetes Association: clinical practice recommendations 2000. Diabetes Care 2000;23(suppl 1): S5–10. 280. Hayner NS, Kjelsberg MO, Epstein FH, et al. Carbohydrate tolerance and diabetes in a total community, Tecumseh, Michigan. 1. Effects of age, sex, and test conditions on one-hour glucose tolerance in adults. Diabetes 1965;14:413–423. 281. Piche ME, Arcand-Bosse JF, Despres JP, et al. What is a normal glucose value? Differences in indexes of plasma glucose homeostasis in subjects with normal fasting glucose. Diabetes Care 2004;27:2470–2477. 282. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998;21:360–367. 283. Meigs JB, Nathan DM, Wilson PW, et al. Metabolic risk factors worsen continuously across the spectrum of nondiabetic 11/24/2006 10:58:09 AM en docr in e disor ders a n d the he a rt glucose tolerance. The Framingham Offspring Study. Ann Intern Med 19(8;128:524–533. 284. Hu G. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia 2003;46:608–617. 285. Qiao Q, Tuomilehto J, Borch-Johnsen K. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 2003;46(suppl 1):M17–21. 286. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998;21:1236–1239. 287. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397–405. 288. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403. 289. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796–2803. 290. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–412. 291. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703– 713. 292. Umpierrez GE, Isaacs SD, Bazargan N, et al. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87: 978–982. 293. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359–1367. 294. Pittas AG, Siegel RD, Lau J. Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials. Arch Intern Med 2004;164:2005–2011. 295. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314:1512–1515. 296. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15:737–754. 297. Melander A, Bitzen PO, Faber O, et al. Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use. Drugs 1989;37:58–72. 298. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001;358:1709–1716. 299. Standl E, Fuchtenbusch M. The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus. Diabetologia 2003;46(suppl 1): M30–36. 300. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333: 541–549. 301. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550–554. 302. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994;121:928–935. CAR108.indd 2323 2323 303. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45: 1661–1669. 304. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351: 1106–1118. 305. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360–372. 306. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995;44:1249–1258. 307. Schwartz S, Raskin P, Fonseca V, et al. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med 1998;338:861–866. 308. Turner RC, Holman RR. Insulin use in NIDDM. Rationale based on pathophysiology of disease. Diabetes Care 1990;13: 1011–1020. 309. Galloway JA. Treatment of NIDDM with insulin agonists or substitutes. Diabetes Care 1990;13:1209–1239. 310. Miyazaki Y, Mahankali A, Wajcberg E, et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:4312–4319. 311. Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169–2176. 312. Tonelli J, Li W, Kishore P, et al. Mechanisms of early insulinsensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 2004;53:1621–1629. 312a. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the Proactive Study. Prospective pioglitazone clinical trial in macrovascular events: a randomised controlled trial. Lancet 2005;366:1279–1289. 313. Idris I, Gray S, Donnelly R. Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia 2003;46:288–290. 314. Zanchi A, Chiolero A, Maillard M, et al. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 2004;89:1140–1145. 315. Avandia (rosiglitazone maleate) package insert. Philadelphia: GlaxoSmithKline Pharmaceuticals, 2000. 316. Actos (pioglitazone hydrochloride) package insert. Lincolnshire, IL: Takeda Pharmaceuticals America, 2002. 317. Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226– 1232. 318. Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003;26:2983– 2989. 319. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256–263. 320. Gerich JE, Campbell PJ. Overview of counterregulation and its abnormalities in diabetes mellitus and other conditions. Diabetes Metab Rev 1988;4:93–111. 321. Clarke WL, Gonder-Frederick LA, Richards FE, et al. Multifactorial origin of hypoglycemic symptom unawareness in IDDM. Association with defective glucose counterregulation and better glycemic control. Diabetes 1991;40:680– 685. 11/24/2006 10:58:09 AM 2324 chapter 322. Amiel SA, Tamborlane WV, Sacca L, et al. Hypoglycemia and glucose counterregulation in normal and insulin-dependent diabetic subjects. Diabetes Metab Rev 1988;4:71–89. 323. Lingenfelser T, Renn W, Sommerwerck U, et al. Compromised hormonal counterregulation, symptom awareness, and neurophysiological function after recurrent short-term episodes of insulin-induced hypoglycemia in IDDM patients. Diabetes 1993;42:610–618. 324. Cryer PE. Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 2004;350:2272–2279. 325. Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993;42: 1683–1689. 326. Cranston I, Lomas J, Maran A, et al. Restoration of hypoglycaemia awareness in patients with long-duration insulindependent diabetes. Lancet 1994;344:283–287. 327. Allen KV, Frier BM. Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention. Endocr Pract 2003;9:530–543. 328. Robinson RT, Harris ND, Ireland RH, et al. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. Diabetes 2003;52:1469–1474. 329. Arauz-Pacheco C, Parrott MA, Raskin P. Hypertension management in adults with diabetes. Diabetes Care 2004;27(suppl 1):S65–67. 330. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:713–720. 331. De Feo P, Bolli G, Perriello G, et al. The adrenergic contribution to glucose counterregulation in type I diabetes mellitus. Dependency on A-cell function and mediation through beta 2–adrenergic receptors. Diabetes 1983;32:887–893. 332. Newman RJ. Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia. Br Med J 1976;2: 447–449. 333. Lager I, Blohme G, Smith U. Effect of cardioselective and nonselective beta-blockade on the hypoglycaemic response in insulin-dependent diabetics. Lancet 1979;1:458–462. 334. Deacon SP, Barnett D. Comparison of atenolol and propranolol during insulin-induced hypoglycaemia. Br Med J 1976;2: 272–273. 335. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991;14:203–209. 336. Pollare T, Lithell H, Selinus I, et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989;298:1152–1157. 337. Stein PP, Black HR. Drug treatment of hypertension in patients with diabetes mellitus. Diabetes Care 1991;14:425–448. 338. Weidmann P, Ferrier C, Saxenhofer H, et al. Serum lipoproteins during treatment with antihypertensive drugs. Drugs 1988; 35(suppl 6):118–134. 339. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321: 868–873. 340. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329: 1456–1462. 341. Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995;346:1080–1084. CAR108.indd 2324 10 8 342. Toto RD. Lessons learned from recent clinical trials in hypertensive diabetics: what’s good for the kidney is good for the heart and brain. Am J Hypertens 2004;17:7S–10S; quiz A2–4. 343. de Zeeuw D. Should albuminuria be a therapeutic target in patients with hypertension and diabetes? Am J Hypertens 2004;17:11S–15S; quiz A2–4. 344. Andersen NH, Mogensen CE. Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease. Curr Hypertens Rep 2004;6:369–376. 345. Sowers JR. Treatment of hypertension in patients with diabetes. Arch Intern Med 2004;164:1850–1857. 346. Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828. 347. Toto RD. Renal insufficiency due to angiotensin-converting enzyme inhibitors. Miner Electrolyte Metab 1994;20:193–200. 348. Garg A. Treatment of diabetic dyslipidemia. Am J Cardiol 1998;81:47B–51B. 349. Haffner SM. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27(suppl 1):S68–71. 350. Sosenko JM, Breslow JL, Miettinen OS, et al. Hyperglycemia and plasma lipid levels: a prospective study of young insulindependent diabetic patients. N Engl J Med 1980;302:650–654. 351. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–696. 352. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–1504. 353. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22. 354. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227– 239. 355. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990;13:153–169. 356. Molnar GD, Berge KG, Rosevear JW, et al. The Effect of Nicotinic Acid in Diabetes Mellitus. Metabolism 1964;13:181–190. 357. Pocotte SL, Ehrenstein G, Fitzpatrick LA. Regulation of parathyroid hormone secretion. Endocr Rev 1991;12:291–301. 358. Khosla S, Ebeling PR, Firek AF, et al. Calcium infusion suggests a “set-point” abnormality of parathyroid gland function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism. J Clin Endocrinol Metab 1993;76:715–720. 359. Brown EM, Pollak M, Hebert SC. Sensing of extracellular Ca2+ by parathyroid and kidney cells: cloning and characterization of an extracellular Ca(2+)-sensing receptor. Am J Kidney Dis 1995;25:506–513. 360. Brown EM, Pollak M, Seidman CE, et al. Calcium-ion-sensing cell-surface receptors. N Engl J Med 1995;333:234–240. 361. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993;366:575–580. 362. Bogin E, Massry SG, Harary I. Effect of parathyroid hormone on rat heart cells. J Clin Invest 1981;67:1215–1227. 363. Katoh Y, Klein KL, Kaplan RA, et al. Parathyroid hormone has a positive inotropic action in the rat. Endocrinology 1981; 109:2252–2254. 364. Schluter KD, Weber M, Piper HM. Parathyroid hormone induces protein kinase C but not adenylate cyclase in adult cardiomyocytes and regulates cyclic AMP levels via protein kinase C- 11/24/2006 10:58:09 AM en docr in e disor ders a n d the he a rt dependent phosphodiesterase activity. Biochem J 1995;310(pt 2):439–444. 365. Schluter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 1998;37:34–41. 366. Mok LL, Nickols GA, Thompson JC, et al. Parathyroid hormone as a smooth muscle relaxant. Endocr Rev 1989;10:420–436. 367. Budayr AA, Nissenson RA, Klein RF, et al. Increased serum levels of a parathyroid hormone-like protein in malignancyassociated hypercalcemia. Ann Intern Med 1989;111:807–812. 368. Henderson JE, Shustik C, Kremer R, et al. Circulating concentrations of parathyroid hormone-like peptide in malignancy and in hyperparathyroidism. J Bone Miner Res 1990;5:105–113. 369. Beall DP, Scofield RH. Milk-alkali syndrome associated with calcium carbonate consumption. Report of 7 patients with parathyroid hormone levels and an estimate of prevalence among patients hospitalized with hypercalcemia. Medicine (Baltimore) 1995;74:89–96. 370. Pollak MR, Brown EM, Chou YH, et al. Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993;75:1297–1303. 371. Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison’s disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore) 1981;60:355–362. 372. Hanley DA, Davison KS. Vitamin d insufficiency in North America. J Nutr 2005;135:332–337. 373. Levis S, Gomez A, Jimenez C, et al. Vitamin D deficiency and seasonal variation in an adult south Florida population. J Clin Endocrinol Metab 2005;90:1557–1562. 374. Mosekilde L. Vitamin D and the elderly. Clin Endocrinol (Oxf) 2005;62:265–281. 375. Daniels J, Goodman AD. Hypertension and hyperparathyroidism. Inverse relation of serum phosphate level and blood pressure. Am J Med 1983;75:17–23. 376. Diamond TW, Botha JR, Wing J, et al. Parathyroid hypertension. A reversible disorder. Arch Intern Med 1986;146:1709– 1712. 377. Lafferty FW, Hubay CA. Primary hyperparathyroidism. A review of the long-term surgical and nonsurgical morbidities as a basis for a rational approach to treatment. Arch Intern Med 1989;149:789–796. 378. Roberts WC, Waller BF. Effect of chronic hypercalcemia on the heart. An analysis of 18 necropsy patients. Am J Med 1981;71: 371–384. 379. Slavich GA, Antonucci F, Sponza E. Primary hyperparathyroidism and angina pectoris. Int J Cardiol 1988;19:266–267. 380. Thandroyen FT, Morris AC, Hagler HK, et al. Intracellular calcium transients and arrhythmia in isolated heart cells. Circ Res 1991;69:810–819. 381. Hedback G, Tisell LE, Bengtsson BA, et al. Premature death in patients operated on for primary hyperparathyroidism. World J Surg 1990;14:829–835; discussion 836. 382. Hedback G, Oden A. Increased risk of death from primary hyperparathyroidism—an update. Eur J Clin Invest 1998;28: 271–276. 383. Palmer M, Adami HO, Bergstrom R, et al. Mortality after surgery for primary hyperparathyroidism: a follow-up of 441 patients operated on from 1956 to 1979. Surgery 1987;102:1–7. 384. Ogard CG, Engholm G, Almdal TP, et al. Increased mortality in patients hospitalized with primary hyperparathyroidism during the period 1977–1993 in Denmark. World J Surg 2004; 28:108–111. 385. Garcia de la Torre N, Wass JA, Turner HE. Parathyroid adenomas and cardiovascular risk. Endocr Relat Cancer 2003;10: 309–322. CAR108.indd 2325 2325 386. Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease—a review. Eur Heart J 2004;25: 1776–1787. 387. Lafferty FW. Primary hyperparathyroidism. Changing clinical spectrum, prevalence of hypertension, and discriminant analysis of laboratory tests. Arch Intern Med 1981;141: 1761–1766. 388. Kovacs L, Goth MI, Szabolcs I, et al. The effect of surgical treatment on secondary hyperaldosteronism and relative hyperinsulinemia in primary hyperparathyroidism. Eur J Endocrinol 1998;138:543–547. 389. Rayner HC, Hasking DJ. Hyperparathyroidism associated with severe hypercalcaemia and myocardial calcification despite minimal bone disease. Br Med J (Clin Res Ed) 1986;293: 1277–1278. 390. Stefenelli T, Wikman-Coffelt J, Wu ST, et al. Calciumdependent fluorescence transients during ventricular fibrillation. Am Heart J 1990;120:590–597. 391. Nuzzo V, Tauchmanova L, Fonderico F, et al. Increased intimamedia thickness of the carotid artery wall, normal blood pressure profile and normal left ventricular mass in subjects with primary hyperparathyroidism. Eur J Endocrinol 2002;147:453– 459. 392. Kosch M, Hausberg M, Kisters K, et al. [Alterations of arterial vessel wall properties in hyperparathyroidism]. Med Klin (Munich) 2000;95:267–272. 393. Kosch M, Hausberg M, Vormbrock K, et al. Studies on flowmediated vasodilation and intima-media thickness of the brachial artery in patients with primary hyperparathyroidism. Am J Hypertens 2000;13:759–764. 394. Kosch M, Hausberg M, Vormbrock K, et al. Impaired flowmediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy. Cardiovasc Res 2000;47:813–818. 395. Kosch M, Hausberg M, Barenbrock M, et al. Arterial distensibility and pulse wave velocity in patients with primary hyperparathyroidism before and after parathyroidectomy. Clin Nephrol 2001;55:303–308. 396. Stefenelli T, Mayr H, Bergler-Klein J, et al. Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med 1993;95:197–202. 397. Stefenelli T, Abela C, Frank H, et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab 1997;82:106–112. 398. Piovesan A, Molineri N, Casasso F, et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 1999;50: 321–328. 399. Almqvist EG, Bondeson AG, Bondeson L, et al. Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy. Surgery 2002;132:1126–1132; discussion 1132. 400. Nappi S, Saha H, Virtanen V, et al. Left ventricular structure and function in primary hyperparathyroidism before and after parathyroidectomy. Cardiology 2000;93:229–233. 401. Procopio M, Magro G, Cesario F, et al. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed type 2 diabetes mellitus in primary hyperparathyroidism. Diabet Med 2002;19:958–961. 402. Hagstrom E, Lundgren E, Lithell H, et al. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clin Endocrinol (Oxf) 2002;56:253–260. 403. Riggs JE. Neurologic manifestations of electrolyte disturbances. Neurol Clin 2002;20:227–239, vii. 11/24/2006 10:58:09 AM 2326 chapter 404. Diercks DB, Shumaik GM, Harrigan RA, et al. Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med 2004;27:153–160. 405. Huddle KR. Cardiac dysfunction in primary hypoparathyroidism. A report of 3 cases. S Afr Med J 1988;73:242–244. 406. Giles TD, Iteld BJ, Rives KL. The cardiomyopathy of hypoparathyroidism. Another reversible form of heart muscle disease. Chest 1981;79:225–229. 407. Rimailho A, Bouchard P, Schaison G, et al. Improvement of hypocalcemic cardiomyopathy by correction of serum calcium level. Am Heart J 1985;109:611–613. 408. Levine SN, Rheams CN. Hypocalcemic heart failure. Am J Med 1985;78:1033–1035. 409. Hurley K, Baggs D. Hypocalcemic cardiac failure in the emergency department. J Emerg Med 2005;28:155–159. 410. Avsar A, Dogan A, Tavli T. A rare cause of reversible dilated cardiomyopathy: hypocalcemia. Echocardiography 2004;21: 609–612. 411. Csanady M, Forster T, Julesz J. Reversible impairment of myocardial function in hypoparathyroidism causing hypocalcaemia. Br Heart J 1990;63:58–60. 412. Holick MF. Vitamin D. A millennium perspective. J Cell Biochem 2003;88:296–307. 413. Krause R, Buhring M, Hopfenmuller W, et al. Ultraviolet B and blood pressure. Lancet 1998;352:709–710. 414. Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997;30:150– 156. 415. Zittermann A, Schleithoff SS, Tenderich G, et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003;41:105–112. 416. Olgun H, Ceviz N, Ozkan B. A case of dilated cardiomyopathy due to nutritional vitamin D deficiency rickets. Turk J Pediatr 2003;45:152–154. 417. Cantorna MT, Hayes CE, DeLuca HF. 1,25–Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996;93:7861–7864. 418. Luscombe CJ, Fryer AA, French ME, et al. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 2001;358:641– 642. 419. Grant WB. An ecologic study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. Cancer 2002;94: 272–281. 420. Chen TC, Holick MF. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 2003;14:423– 430. 421. Hypponen E, Laara E, Reunanen A, et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358:1500–1503. 422. Martin KJ, Akhtar I, Gonzalez EA. Parathyroid hormone: new assays, new receptors. Semin Nephrol 2004;24:3–9. 423. Goodman WG, Juppner H, Salusky IB, et al. Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Kidney Int 2003;63:1–11. 424. Heath H 3rd Familial benign (hypocalciuric) hypercalcemia. A troublesome mimic of mild primary hyperparathyroidism. Endocrinol Metab Clin North Am 1989;18:723–740. 425. Marx SJ, Attie MF, Levine MA, et al. The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fi fteen kindreds. Medicine (Baltimore) 1981;60:397–412. 426. Holick MF. Sunlight and vitamin D. Both good for cardiovascular health. J Gen Intern Med 2002;17:733–735. 427. Malabanan A, Veronikis IE, Holick MF. Redefi ning vitamin D insufficiency. Lancet 1998;351:805–806. CAR108.indd 2326 10 8 428. Holick MF. Vitamin D importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004;79:362–371. 429. Bilezikian JP, Silverberg SJ. Clinical spectrum of primary hyperparathyroidism. Rev Endocr Metab Disord 2000;1:237– 245. 430. Bilezikian JP, Potts JT Jr, Fuleihan Gel H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002;87:5353–5361. 431. Silverberg SJ, Bone HG 3rd, Marriott TB, et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 1997;337:1506–1510. 432. Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:5644– 5649. 433. Ogata H, Ritz E, Odoni G, et al. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 2003;14:959–967. 434. Bilezikian JP, Brandi ML, Rubin M, et al. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 2005;257:6–17. 435. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516–1525. 436. Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:135–141. 437. Attie MF. Treatment of hypercalcemia. Endocrinol Metab Clin North Am 1989;18:807–828. 438. Bilezikian JP. Management of acute hypercalcemia. N Engl J Med 1992;326:1196–1203. 439. Binstock ML, Mundy GR. Effect of calcitonin and glucocorticoids in combination on the hypercalcemia of malignancy. Ann Intern Med 1980;93:269–272. 440. Mundy GR, Wilkinson R, Heath DA. Comparative study of available medical therapy for hypercalcemia of malignancy. Am J Med 1983;74:421–432. 441. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005;352:373–379. 442. Adams JS. Vitamin D metabolite-mediated hypercalcemia. Endocrinol Metab Clin North Am 1989;18:765–778. 443. Sutton RA. Diuretics and calcium metabolism. Am J Kidney Dis 1985;5:4–9. 444. Stier CT Jr, Itskovitz HD. Renal calcium metabolism and diuretics. Annu Rev Pharmacol Toxicol 1986;26:101–116. 445. Heaney RP, Dowell MS, Hale CA, et al. Calcium absorption varies within the reference range for serum 25–hydroxyvitamin D. J Am Coll Nutr 2003;22:142–146. 446. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889–895. 447. Lazar MA. Steroid and thyroid hormone receptors. Endocrinol Metab Clin North Am 1991;20:681–695. 448. Fazio S, Palmieri EA, Lombardi G, et al. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 2004;59:31–50. 449. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501–509. 450. Ojamaa K, Klemperer JD, Klein I. Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 1996;6:505–512. 451. Toft AD, Boon NA. Thyroid disease and the heart. Heart 2000;84:455–460. 452. Dillmann WH. Biochemical basis of thyroid hormone action in the heart. Am J Med 1990;88:626–630. 11/24/2006 10:58:10 AM en docr in e disor ders a n d the he a rt 453. Carr AN, Kranias EG. Thyroid hormone regulation of calcium cycling proteins. Thyroid 2002;12:453–457. 454. Litten RZ 3rd, Martin BJ, Low RB, et al. Altered myosin isozyme patterns from pressure-overloaded and thyrotoxic hypertrophied rabbit hearts. Circ Res 1982;50:856–864. 455. Holubarsch C, Goulette RP, Litten RZ, et al. The economy of isometric force development, myosin isoenzyme pattern and myofibrillar ATPase activity in normal and hypothyroid rat myocardium. Circ Res 1985;56:78–86. 456. Kim D, Smith TW, Marsh JD. Effect of thyroid hormone on slow calcium channel function in cultured chick ventricular cells. J Clin Invest 1987;80:88–94. 457. MacKinnon R, Gwathmey JK, Allen PD, et al. Modulation by the thyroid state of intracellular calcium and contractility in ferret ventricular muscle. Circ Res 1988;63:1080–1089. 458. Poggesi C, Everts M, Polla B, et al. Influence of thyroid state on mechanical restitution of rat myocardium. Circ Res 1987; 60:142–151. 459. Klein I, Hong C. Effects of thyroid hormone on cardiac size and myosin content of the heterotopically transplanted rat heart. J Clin Invest 1986;77:1694–1698. 460. Korecky B, Zak R, Schwartz K, et al. Role of thyroid hormone in regulation of isomyosin composition, contractility, and size of heterotopically isotransplanted rat heart. Circ Res 1987; 60:824–830. 461. Ross DS. Serum thyroid-stimulating hormone measurement for assessment of thyroid function and disease. Endocrinol Metab Clin North Am 2001;30:245–264, vii. 462. Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997;126:63–73. 463. Martino E, Safran M, Aghini-Lombardi F, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984;101:28–34. 464. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991;91:507–511. 465. Burger A, Dinichert D, Nicod P, et al. Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyrotropin. A drug influencing peripheral metabolism of thyroid hormones. J Clin Invest 1976;58:255–259. 466. Roti E, Minelli R, Gardini E, et al. Thyrotoxicosis followed by hypothyroidism in patients treated with amiodarone. A possible consequence of a destructive process in the thyroid. Arch Intern Med 1993;153:886–892. 467. Canaris GJ, Steiner JF, Ridgway EC. Do traditional symptoms of hypothyroidism correlate with biochemical disease? J Gen Intern Med 1997;12:544–550. 468. Fredlund BO, Olsson SB. Long QT interval and ventricular tachycardia of “torsade de pointe” type in hypothyroidism. Acta Med Scand 1983;213:231–235. 469. Slovis C, Jenkins R. ABC of clinical electrocardiography: Conditions not primarily affecting the heart. BMJ 2002;324: 1320–1323. 470. Polikar R, Burger AG, Scherrer U, et al. The thyroid and the heart. Circulation 1993;87:1435–1441. 471. Ladenson PW. Recognition and management of cardiovascular disease related to thyroid dysfunction. Am J Med 1990;88: 638–641. 472. Fommei E, Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab 2002;87:1996– 2000. 473. Fletcher AK, Weetman AP. Hypertension and hypothyroidism. J Hum Hypertens 1998;12:79–82. 474. Streeten DH, Anderson GH Jr, Howland T, et al. Effects of thyroid function on blood pressure. Recognition of hypothyroid hypertension. Hypertension 1988;11:78–83. CAR108.indd 2327 2327 475. Bengel FM, Nekolla SG, Ibrahim T, et al. Effect of thyroid hormones on cardiac function, geometry, and oxidative metabolism assessed noninvasively by positron emission tomography and magnetic resonance imaging. J Clin Endocrinol Metab 2000;85:1822–1827. 476. Graettinger JS, Muenster JJ, Checchia CS, et al. A correlation of clinical and hemodynamic studies in patients with hypothyroidism. J Clin Invest 1958;37:502–510. 477. Wieshammer S, Keck FS, Waitzinger J, et al. Left ventricular function at rest and during exercise in acute hypothyroidism. Br Heart J 1988;60:204–211. 478. Vora J, O’Malley BP, Petersen S, et al. Reversible abnormalities of myocardial relaxation in hypothyroidism. J Clin Endocrinol Metab 1985;61:269–272. 479. Levey GS, Skelton CL, Epstein SE. Decreased myocardial adenyl cyclase activity in hypothyroidism. J Clin Invest 1969; 48:2244–2250. 480. Zimmerman J, Yahalom J, Bar-On H. Clinical spectrum of pericardial effusion as the presenting feature of hypothyroidism. Am Heart J 1983;106:770–771. 481. Steinberg AD. Myxedema and coronary artery disease—a comparative autopsy study. Ann Intern Med 1968;68:338–344. 482. Biondi B, Palmieri EA, Lombardi G, et al. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med 2002;137: 904–914. 483. Brenta G, Mutti LA, Schnitman M, et al. Assessment of left ventricular diastolic function by radionuclide ventriculography at rest and exercise in subclinical hypothyroidism, and its response to L-thyroxine therapy. Am J Cardiol 2003;91:1327– 1330. 484. Vitale G, Galderisi M, Lupoli GA, et al. Left ventricular myocardial impairment in subclinical hypothyroidism assessed by a new ultrasound tool: pulsed tissue Doppler. J Clin Endocrinol Metab 2002;87:4350–4355. 485. Di Bello V, Monzani F, Giorgi D, et al. Ultrasonic myocardial textural analysis in subclinical hypothyroidism. J Am Soc Echocardiogr 2000;13:832–840. 486. Biondi B, Fazio S, Palmieri EA, et al. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab 1999;84:2064–2067. 487. Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid 2000;10:665–679. 488. Hak AE, Pols HA, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000;132:270–278. 489. Duntas LH. Thyroid disease and lipids. Thyroid 2002;12: 287–293. 490. Duntas LH, Mantzou E, Koutras DA. Circulating levels of oxidized low-density lipoprotein in overt and mild hypothyroidism. Thyroid 2002;12:1003–1007. 491. Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160: 526–534. 492. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004;291:228–238. 493. Morris MS, Bostom AG, Jacques PF, et al. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. Atherosclerosis 2001;155:195–200. 494. Fish LH, Mariash CN. Hyperprolactinemia, infertility, and hypothyroidism. A case report and literature review. Arch Intern Med 1988;148:709–711. 495. Beyer IW, Karmali R, Demeester-Mirkine N, et al. Serum creatine kinase levels in overt and subclinical hypothyroidism. Thyroid 1998;8:1029–1031. 11/24/2006 10:58:10 AM 2328 chapter 496. Robuschi G, Safran M, Braverman LE, et al. Hypothyroidism in the elderly. Endocr Rev 1987;8:142–153. 497. Keating FR Jr, Parkin TW, Selby JB, et al. Treatment of heart disease associated with myxedema. Prog Cardiovasc Dis 1961; 3:364–381. 498. Fish LH, Schwartz HL, Cavanaugh J, et al. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 1987;316:764–770. 499. Hennessey JV, Evaul JE, Tseng YC, et al. L-thyroxine dosage: a reevaluation of therapy with contemporary preparations. Ann Intern Med 1986;105:11–15. 500. Gharib H, Tuttle RM, Baskin HJ, et al. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab 2005;90:581–585; discussion 586–587. 501. Col NF, Surks MI, Daniels GH. Subclinical thyroid disease: clinical applications. JAMA 2004;291:239–243. 502. Roberts CG, Ladenson PW. Hypothyroidism. Lancet 2004;363: 793–803. 503. Ladenson PW, Levin AA, Ridgway EC, et al. Complications of surgery in hypothyroid patients. Am J Med 1984;77:261–266. 504. Drucker DJ, Burrow GN. Cardiovascular surgery in the hypothyroid patient. Arch Intern Med 1985;145:1585–1587. 505. Wehmann RE, Gregerman RI, Burns WH, et al. Suppression of thyrotropin in the low-thyroxine state of severe nonthyroidal illness. N Engl J Med 1985;312:546–552. 506. Hamblin PS, Dyer SA, Mohr VS, et al. Relationship between thyrotropin and thyroxine changes during recovery from severe hypothyroxinemia of critical illness. J Clin Endocrinol Metab 1986;62:717–722. 507. Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab 1986;63:1–8. 508. Chopra IJ, Hershman JM, Pardridge WM, et al. Thyroid function in nonthyroidal illnesses. Ann Intern Med 1983;98:946– 957. 509. Wartofsky L, Burman KD. Alterations in thyroid function in patients with systemic illness: the “euthyroid sick syndrome”. Endocr Rev 1982;3:164–217. 510. Tibaldi JM, Surks MI. Effects of nonthyroidal illness on thyroid function. Med Clin North Am 1985;69:899–911. 511. Kaptein EM, Weiner JM, Robinson WJ, et al. Relationship of altered thyroid hormone indices to survival in nonthyroidal illnesses. Clin Endocrinol (Oxf) 1982;16:565–574. 512. Surks MI, Hupart KH, Pan C, et al. Normal free thyroxine in critical nonthyroidal illnesses measured by ultrafiltration of undiluted serum and equilibrium dialysis. J Clin Endocrinol Metab 1988;67:1031–1039. 513. Becker RA, Vaughan GM, Ziegler MG, et al. Hypermetabolic low triiodothyronine syndrome of burn injury. Crit Care Med 1982;10:870–875. 514. Franklyn JA, Gammage MD, Ramsden DB, et al. Thyroid status in patients after acute myocardial infarction. Clin Sci (Lond) 1984;67:585–590. 515. Hamilton MA, Stevenson LW, Luu M, et al. Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol 1990;16:91–95. 516. Holland FW, 2nd, Brown PS Jr, Weintraub BD, et al. Cardiopulmonary bypass and thyroid function: a “euthyroid sick syndrome”. Ann Thorac Surg 1991;52:46–50. 517. Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 1995;333:1522–1527. 518. Bettendorf M, Schmidt KG, Tiefenbacher U, et al. Transient secondary hypothyroidism in children after cardiac surgery. Pediatr Res 1997;41:375–379. CAR108.indd 2328 10 8 519. Klein I, Ojamaa K. Thyroid hormone treatment of congestive heart failure. Am J Cardiol 1998;81:490–491. 520. Klemperer JD. Thyroid hormone and cardiac surgery. Thyroid 2002;12:517–521. 521. Vargas MT, Briones-Urbina R, Gladman D, et al. Antithyroid microsomal autoantibodies and HLA-DR5 are associated with postpartum thyroid dysfunction: evidence supporting an autoimmune pathogenesis. J Clin Endocrinol Metab 1988;67:327– 333. 522. Becks GP, Burrow GN. Thyroid disease and pregnancy. Med Clin North Am 1991;75:121–150. 523. Lazarus JH, Othman S. Thyroid disease in relation to pregnancy. Clin Endocrinol (Oxf) 1991;34:91–98. 524. DeGroot WJ, Leonard JJ. Hyperthyroidism as a high cardiac output state. Am Heart J 1970;79:265–275. 525. Sandler G, Wilson GM. The nature and prognosis of heart disease in thyrotoxicosis. A review of 150 patients treated with 131 I. Q J Med 1959;28:347–369. 526. Ikram H. The nature and prognosis of thyrotoxic heart disease. Q J Med 1985;54:19–28. 527. Forfar JC, Muir AL, Sawers SA, et al. Abnormal left ventricular function in hyperthyroidism: evidence for a possible reversible cardiomyopathy. N Engl J Med 1982;307:1165–1170. 528. Kahaly GJ, Kampmann C, Mohr-Kahaly S. Cardiovascular hemodynamics and exercise tolerance in thyroid disease. Thyroid 2002;12:473–481. 529. Biondi B, Fazio S, Cuocolo A, et al. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1996;81:4224–4228. 530. Dillmann WH. Cellular action of thyroid hormone on the heart. Thyroid 2002;12:447–452. 531. Osman F, Franklyn JA, Daykin J, et al. Heart rate variability and turbulence in hyperthyroidism before, during, and after treatment. Am J Cardiol 2004;94:465–469. 532. Ojamaa K, Klein I, Sabet A, et al. Changes in adenylyl cyclase isoforms as a mechanism for thyroid hormone modulation of cardiac beta-adrenergic receptor responsiveness. Metabolism 2000;49:275–279. 533. Hoit BD, Khoury SF, Shao Y, et al. Effects of thyroid hormone on cardiac beta-adrenergic responsiveness in conscious baboons. Circulation 1997;96:592–598. 534. Liggett SB, Shah SD, Cryer PE. Increased fat and skeletal muscle beta-adrenergic receptors but unaltered metabolic and hemodynamic sensitivity to epinephrine in vivo in experimental human thyrotoxicosis. J Clin Invest 1989;83:803– 809. 535. Klein I, Ojamaa K. Thyrotoxicosis and the heart. Endocrinol Metab Clin North Am 1998;27:51–62. 536. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249–1252. 537. Gilligan DM, Ellenbogen KA, Epstein AE. The management of atrial fibrillation. Am J Med 1996;101:413–421. 538. Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992;327:94–98. 539. Shimizu T, Koide S, Noh JY, et al. Hyperthyroidism and the management of atrial fibrillation. Thyroid 2002;12:489– 493. 540. Petersen P. Thromboembolic complications in atrial fibrillation. Stroke 1990;21:4–13. 541. Petersen P, Hansen JM. Stroke in thyrotoxicosis with atrial fibrillation. Stroke 1988;19:15–18. 542. Glikson M, Freimark D, Leor R, et al. Unstable anginal syndrome and pulmonary oedema due to thyrotoxicosis. Postgrad Med J 1991;67:81–83. 543. Toft AD. Clinical practice. Subclinical hyperthyroidism. N Engl J Med 2001;345:512–516. 11/24/2006 10:58:10 AM en docr in e disor ders a n d the he a rt 544. Auer J, Scheibner P, Mische T, et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 2001; 142:838–842. 545. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905–917. 546. Forfar JC, Feek CM, Miller HC, et al. Atrial fibrillation and isolated suppression of the pituitary-thyroid axis: response to specific antithyroid therapy. Int J Cardiol 1981;1:43–48. 547. Grund FM, Niewoehner CB. Hyperthyroxinemia in patients receiving thyroid replacement therapy. Arch Intern Med 1989; 149:921–924. 548. Fazio S, Biondi B, Carella C, et al. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade. J Clin Endocrinol Metab 1995;80:2222–2226. 549. Bartalena L, Brogioni S, Grasso L, et al. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab 1996;81:2930–2933. 550. Bartalena L, Grasso L, Brogioni S, et al. Serum interleukin-6 in amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 1994;78:423–427. 551. Isley WL, Dahl S, Gibbs H. Use of esmolol in managing a thyrotoxic patient needing emergency surgery. Am J Med 1990; 89:122–123. 552. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934–959. 553. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001;92:2204–2210. 554. Berge T, Linell F. Carcinoid tumours. Frequency in a defi ned population during a 12–year period. Acta Pathol Microbiol Scand [A] 1976;84:322–330. 555. Akerstrom G, Hellman P, Hessman O, et al. Management of midgut carcinoids. J Surg Oncol 2005;89:161–169. 556. Pearse AG. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 1969;17:303–313. 557. Moller JE, Connolly HM, Rubin J, et al. Factors associated with progression of carcinoid heart disease. N Engl J Med 2003; 348:1005–1015. 558. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist 2005;10:123–131. 559. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340:858–868. 560. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987;5:1502–1522. 561. Zuetenhorst JM, Korse CM, Bonfrer JM, et al. Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid tumors. Clin Chem 2004;50: 1634–1639. 562. Oberg K, Theodorsson-Norheim E, Norheim I. Motilin in plasma and tumor tissues from patients with the carcinoid syndrome. Possible involvement in the increased frequency of bowel movements. Scand J Gastroenterol 1987;22:1041–1048. 563. Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and management. Heart 2004;90:1224–1228. 564. Lundin L, Norheim I, Landelius J, et al. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasounddetectable cardiac abnormalities. Circulation 1988;77:264–269. 565. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790–795. 566. Ferrans VJ, Roberts WC. The carcinoid endocardial plaque; an ultrastructural study. Hum Pathol 1976;7:387–409. 567. Modlin IM, Shapiro MD, Kidd M. Carcinoid tumors and fibrosis: an association with no explanation. Am J Gastroenterol 2004;99:2466–2478. CAR108.indd 2329 2329 568. Zuetenhorst JM, Bonfrer JM, Korse CM, et al. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 2003;97:1609–1615. 569. Jick H, Vasilakis C, Weinrauch LA, et al. A population-based study of appetite-suppressant drugs and the risk of cardiacvalve regurgitation. N Engl J Med 1998;339:719–724. 570. Weissman NJ, Tighe JF Jr, Gottdiener JS, et al. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med 1998;339:725–732. 571. Khan MA, Herzog CA, St Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998;339:713–718. 572. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581–588. 573. Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188–1196. 574. Schweizer W, Gloor F, Von B, et al. Carcinoid heart disease with left-sided lesions. Circulation 1964;29:253–257. 575. Strickman NE, Rossi PA, Massumkhani GA, et al. Carcinoid heart disease: a clinical pathologic, and therapeutic update. Curr Probl Cardiol 1982;6:1–42. 576. Chaowalit N, Connolly HM, Schaff HV, et al. Carcinoid heart disease associated with primary ovarian carcinoid tumor. Am J Cardiol 2004;93:1314–1315. 577. Pandya UH, Pellikka PA, Enriquez-Sarano M, et al. Metastatic carcinoid tumor to the heart: echocardiographicpathologic study of 11 patients. J Am Coll Cardiol 2002;40:1328– 1332. 578. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999;86:858–865. 579. Kema IP, Schellings AM, Meiborg G, et al. Influence of a serotonin- and dopamine-rich diet on platelet serotonin content and urinary excretion of biogenic amines and their metabolites. Clin Chem 1992;38:1730–1736. 580. Meijer WG, Kema IP, Volmer M, et al. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem 2000;46:1588–1596. 581. Kema IP, Willemse PH, De Vries EG. Carcinoid tumors. N Engl J Med 1999;341:453–454; author reply 454–455. 582. Taal BG, Hoefnagel CA, Valdes Olmos RA, et al. Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours. Eur J Cancer 1996; 32A:1924–1932. 583. Janson ET, Westlin JE, Eriksson B, et al. [111In-DTPA-DPhe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994;131:577–581. 584. Hoegerle S, Altehoefer C, Ghanem N, et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 2001;220:373–380. 585. Oberg K, Eriksson B, Janson ET. The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors. Ann N Y Acad Sci 1994;733:471–478. 586. Connolly HM. Carcinoid heart disease: medical and surgical considerations. Cancer Control 2001;8:454–460. 587. Zuetenhorst JM, Korse CM, Bonfrer JM, et al. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer 2004;90: 2073–2079. 11/24/2006 10:58:10 AM 2330 chapter 588. Lamberts SW, van der Lely AJ, de Herder WW, et al. Octreotide. N Engl J Med 1996;334:246–254. 589. Wymenga AN, Eriksson B, Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999;17:1111. 590. Kvols LK, Martin JK, Marsh HM, et al. Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med 1985; 313:1229–1230. CAR108.indd 2330 10 8 591. Anderson AS, Krauss D, Lang R. Cardiovascular complications of malignant carcinoid disease. Am Heart J 1997;134:693– 702. 592. Connolly HM, Schaff HV, Mullany CJ, et al. Surgical management of left-sided carcinoid heart disease. Circulation 2001;104: I36–40. 593. Connolly HM, Nishimura RA, Smith HC, et al. Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol 1995;25:410–416. 11/24/2006 10:58:10 AM